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Executive Summary 
 
Background 
The National Awareness and Early Diagnosis Initiative (NAEDI) has been established in England as 
part of the Government’s strategy to improve cancer outcomes. The NAEDI consists of four work 
streams: 
(1) Raising public awareness and promoting earlier presentation by patients  
(2) Optimising clinical practice and systems  
(3) Improving GP access to diagnostics   
(4) Research, evaluation and monitoring.  
This project focuses on raising public awareness and promoting earlier presentation by patients with 
colorectal cancer (CRC).  
 
Aims 
To identify the effectiveness and design of public awareness programmes which aim to encourage 
early detection of CRC, and to estimate the cost-effectiveness of such programmes. 
 
Systematic Review 
A systematic review was conducted to identify studies which assessed the efficacy of public 
awareness programmes about CRC delivered to whole populations or discrete subpopulations, with 
follow-up greater than one day and which did not involve one-to-one attention. A basic logic model 
was constructed, and stages within that model were extracted as study outcomes. Outcomes 
included: changes in campaign awareness, knowledge, attitudes, beliefs and intentions, screening 
uptake, GP visits, GP referrals, diagnoses and survival. Key electronic databases and grey literature 
sources were searched. Studies were selected, data extracted and quality assessed by one reviewer, 
and a narrative synthesis conducted. To describe the scope and variety of interventions in the 
literature, a mapping review of studies which narrowly missed inclusion but which described 
interventions which may be of interest to the review question was also conducted. 
 
Eleven studies were included in the review. Four described interventions which aimed to increase 
self-presentation through awareness of symptoms, and seven described interventions which aimed to 
increase compliance with screening guidelines. The risk of bias within the studies was moderate to 
high and all results should be interpreted with caution. All studies reported mostly positive results that 
generally supported the early stages of the basic logic model such as awareness and knowledge. 
However, there was very little evidence to inform the final stages of the logic model, where increased 
self-presentation or screening attendance is expected to be associated with early detection. Only one 
study reported information relating to diagnoses of CRC, and in this case there was an increase in 
diagnoses via the urgent referral route, but there was only a non-significant increase in diagnoses 
with no spread (outcome as defined in the study; nodal or distal metastases). It is possible that use of 
a dichotomous outcome (spread or no spread) is not sensitive enough to capture a shift in stage at 
presentation. The review did not identify any evidence relating to changes in survival resulting from 
the use of public awareness programmes. 
 
Interventions designed to reach black and minority ethnic or disadvantaged subpopulations were also 
generally successful in achieving an improvement in outcomes at some stage in the logic model. 
Studies which incorporated community involvement in the design of the intervention reported highly 
individualised methods of communicating similar messages. The methods were often creative and 
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engaging, including plays, games and comedy, and were often delivered in unusual settings such as 
pubs, barbers’ and bingo halls.  
 
The mapping review of excluded studies described whether interventions were delivered to 
populations, groups or had an individual component, whether interventions were designed to be 
culturally relevant or had a bilingual aspect, what types of media were employed, what topics were 
covered, whether practical help was provided and whether screening (usually faecal occult blood test) 
was provided with the intervention. Most studies reported positive results.  
 
Cost-effectiveness analysis 
Several studies with the potential to contain data to inform the cost-effectiveness modelling were 
identified by the systematic review. However, the only study which collected data on changes in CRC 
incidence due to the campaign (essential for the modelling) was the pilot ‘signs and symptoms’ 
campaign run in the South West and East of England in January 2011.  
 
Data from the ‘signs and symptoms’ campaign pilot were analysed, including: changes in GP 
attendances, secondary care appointments, CRC incidence, screening uptake and campaign running 
costs. Available data illustrated an increase in the number of GP attendances, secondary care 
appointments, colonoscopy activity and CRC incidence as a result of the campaign. The increase in 
GP attendances observed was associated with considerable uncertainty dues to large variations 
between practices and a possible change in symptom coding. Data on CRC incidence suggested a 
possible increase in incidence for a period of 1 month. Data on CRC incidence by stage involved very 
small numbers so it was not possible to draw any significant conclusions. No significant change in 
screening uptake which could be attributed to the campaign was observed. 
 
An existing CRC screening model was adapted to incorporate the costs and benefits of an awareness 
campaign. The analysis captures the direct costs of the campaign, the costs of any additional GP 
consultations/appointments in secondary care resulting from the campaign, and the expected benefits 
of the campaign resulting from earlier diagnosis or a change in screening uptake. The campaign 
effects were modelled as a temporary increase in the transition probabilities associated with 
symptomatic presentation with cancer. 
 
Due to limitations of the pilot data available it was necessary to make several modelling assumptions: 
• The duration of the effect of the campaign was assumed to be short-term with an increase in 
CRC incidence only observed for one month following the campaign. 
• The campaign was assumed to have the same proportional effect on the presentation rates 
for CRC regardless of stage.  
• The campaign was assumed to have the same proportional effect on presentation rates for all 
age groups. 
• Of the increases in GP consultations and GP referrals, it was assumed that 50% were 
‘additional’ (i.e. would not have presented in the absence of the campaign) as opposed to 
‘earlier’. 
 
Model predictions for no awareness campaign, a one-off awareness campaign and an annual 
awareness campaign for five years were produced. The results reflect model predictions for effects on 
incidence for the lifetime of the entire current population of England aged over 30. Predicted total 
costs were broken down to include: campaign costs, CRC treatment costs, and costs associated with 
additional GP attendances and referrals. Total QALYs, changes in cancer incidence, cancer stage 
distribution, and cancer mortality were also estimated.  
 
Even though the campaign was assumed to have the same proportional effect on the presentation 
rates for CRC regardless of stage, the additional incidence due to the campaign corresponds to 
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persons presenting earlier than they would have in the absence of the campaign. This earlier 
presentation results in a change in the stage distribution over the following few years which has a 
direct impact on CRC mortality. In the base-case model the campaign caused an increase in the 
number of cases of Dukes’ stage A-C presenting symptomatically, and a decrease in the number of 
cases of stage D. Overall, an increase in symptomatic presentation and a small decrease in 
screen/surveillance detected cases is predicted. The increase in overall CRC incidence corresponds 
to a decrease in the number of persons dying with undiagnosed CRC. A significant reduction in CRC 
specific deaths was seen which was due to the reduction in the number of cases of CRC presenting in 
stage D. This reduction in deaths corresponded to an increase in QALYs gained. 
 
The results show a reduction in total costs associated with screening caused by a decrease in the 
number of positives at screening since more CRC presents symptomatically. An increase in CRC 
treatment costs is seen for two reasons. Firstly, CRC is presenting at younger ages which are 
associated with higher treatment costs. Secondly, there is a shift of cases from stage D to Dukes’ C, 
and Dukes’ C CRC is associated with higher treatment costs than stage D. Costs associated with 
increased GP consultations and referrals account for only a small proportion of total costs and are 
considerably less than the cost of the campaign itself.  
 
The economic analysis suggests that a one-off awareness campaign causing an increase in 
presentation rates of 10% for one month would be associated with a total cost of £5.5 million, would 
be expected to prevent 66 deaths from CRC, and, result in a gain of 404 QALYs. The incremental 
cost-effectiveness ratio (ICER) for the one-off awareness campaign was £13,496 per QALY gained 
compared to ‘no campaign’ giving a net monetary benefit (NMB) of £2.6 million (with a willingness-to-
pay threshold of £20K). Assuming that a repeated annual campaign would have similar effects, a 5-
year repeated campaign is expected to have a similar ICER of approximately £13,032 per QALY 
gained whilst providing a NMB of £13 million. Scenario analyses suggest that the ICER increases 
slightly if a higher proportion of the increase in GP consultations/referrals was additional as opposed 
to earlier. If the duration of the effects of the campaign on CRC incidence were assumed to last for 3 
months rather than 1 month, expected QALY gains would increase considerably and the ICER would 
reduce to approximately £4,500 per QALY. Scenario analyses also indicated that results were highly 
sensitive to both the magnitude and stage distribution of the immediate increase in incidence due to 
the campaign. For example, if the magnitude of the increase was just 5% and restricted to Dukes C 
and stage D CRC then the ICER is approximately £55,000 per QALY. An exploratory analysis which 
compared the benefits of an awareness campaign (that increased symptomatic presentation rates by 
10% for 1 month) to a screening campaign (that reduced the number of persons never attending 
screening by 10%) demonstrated that the screening campaign would reduce five times the number of 
CRC deaths compared to the awareness campaign. 
 
Conclusions and Research Recommendations 
Research on interventions to increase early detection of CRC (through patient awareness campaigns 
to increase self-presentation or to increase screening attendance) show generally positive results at 
all stages of the logic model. However, there is only a small amount of evidence towards the end of 
the logic model, and the available evidence throughout is not of high quality due to study design 
(mostly before-after studies), and a potentially high risk of bias. It was not possible to draw 
comparative conclusions between interventions or which components of interventions conferred the 
positive effects. There is a lack of evidence to inform the link between increased self-presentation and 
screening attendance to earlier detection of CRC, though it should be noted that all evidence relating 
to this came from the US.  
 
The data available from the ‘signs and symptoms’ pilot campaign which was used in the cost-
effectiveness modelling was associated with limitations and considerable uncertainty. A priority for 
future research is to co-ordinate and maximise the evaluation and dissemination of efforts that have 
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already been made to increase CRC awareness. For example, clear reporting of completeness of 
data, and comparison with non-intervention regions are important. To establish the potential 
effectiveness and cost-effectiveness of such a campaign, information on ‘duration of effect of 
campaign’, ‘effect of campaign on CRC incidence’ and ‘effect of campaign by age’ are of importance. 
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 1. Introduction 
 
Cancer survival rates in England are poor compared to several other European countries.[1]  It has 
been estimated that if 5-year survival rates for colorectal cancer (CRC) in England matched those for 
the best countries in Europe, around 1,700 deaths per year would be avoided. Similarly across all 
cancer types a total of 10,000 deaths could be avoided. There is increasing recognition that a 
considerable proportion of these avoidable deaths relate to late diagnosis.[2]  
 
A National Awareness and Early Diagnosis Initiative (NAEDI) has been established in England as part 
of the Government’s strategy to improve cancer outcomes.[3] The NAEDI consists of four work 
streams: (1) raising public awareness and promoting earlier presentation by patients, (2) optimising 
clinical practice and systems, (3) improving GP access to diagnostics and (4) research, evaluation 
and monitoring.  
 
This project focuses on raising public awareness and promoting earlier presentation by patients with 
CRC. A similar report considering lung cancer is due to follow. This report aims to address the 
following questions: 
(1) What methods for raising public awareness and promoting earlier presentation by patients 
have been shown to be effective? 
(2) How cost-effective are methods for raising public awareness and promoting earlier 
presentation by patients? 
 
Evidence on the efficacy of a range of early presentation interventions was obtained by undertaking a 
systematic review. The review included both early awareness interventions and interventions which 
aimed to increase screening attendance. In addition, a mapping review was performed, which 
summarised interventions from studies which narrowly missed the inclusion criteria. Data were also 
available from the English bowel cancer signs and symptoms campaign which was piloted in January 
2011 and this is analysed here. [4] 
 
Data from the campaign pilot were used to inform an assessment of the cost-effectiveness of such a 
campaign using a mathematical model. This analysis captures the direct costs of the campaign, the 
costs of any additional GP consultations/appointments in secondary care resulting from the campaign, 
and benefits of the campaign in the form of earlier diagnosis and improved screening uptake. 
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 2. Systematic Review 
 
2.1. Background 
Awareness raising campaigns in healthcare take many forms. Simple interventions may make use 
of a leaflet distributed through GP waiting rooms, through mail-outs or via community 
organisations. Interventions designed to reach as many people as possible may include wide-
ranging media campaigns with billboards, TV adverts, newspaper articles and so on. Interventions 
designed to help those with particular needs such as literacy or language barriers, may take a 
small group or one-to-one approach to deliver the message and help remove barriers to 
screening or early presentation to a GP. Campaigns usually aim to increase knowledge of a 
condition or disease (for example: prevalence, prognosis, risk factors, symptoms) and may 
attempt to influence people’s beliefs about the disease and the importance and benefits of 
attending screening or getting symptoms checked. Interventions may also help to remove 
practical barriers such as access to a diagnostic test, affording transport to get screening/attend 
clinics, or having someone to go with them to an appointment.  
 
Early presentation of CRC can be achieved through two main routes:  
1) Encouraging people to stay up to date with regular screening and  
2) Raising awareness of the symptoms of CRC and encouraging people to visit their doctor if they 
have the symptoms. 
 
A basic logic model to represent these routes is presented in Figure 1. This model was 
constructed by the review authors based on their understanding of the pathways involved. 
 
Figure 1 A basic logic model for increasing early detection of CRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcomes included in review 
 
   
Population 
Δ Lifestyle 
↑ Awareness 
of campaign 
↑ Knowledge 
(of CRC, 
symptoms,  
screening 
guidelines, 
risks etc.) 
↓ Barriers 
Δ Beliefs and 
emotions 
Δ Attitudes 
and intentions 
Δ Behaviour 
↑ Screening 
attendance 
↑ Self-presentation 
to GP due to 
symptoms 
Earlier 
presentation 
↑ Survival 
↓ Morbidity 
Intervention 
13 
 
 
↑, increase; ↓, decrease; Δ, change; GP, general practitioner; CRC, colorectal cancer 
 
 
2.2. Aims 
This report aims to provide more detailed information than has been available to date on the likely 
costs and benefits of early detection interventions in colorectal cancer to assist the Department of 
Health in policy making. In order to establish the efficacy of population-based interventions 
designed to improve early detection, a systematic review was undertaken. In addition, a mapping 
review[5] of interventions from studies which narrowly missed inclusion was conducted to 
describe the scope and variety of interventions reported in the literature. 
 
Interventions to support GPs to assess, investigate and refer more appropriately or to provide 
GPs with better access to diagnostic tests were beyond the scope of this review.  
 
 
2.3. Methods 
A comprehensive search using terms for ‘colorectal cancer’ combined with ‘health promotion’ or 
‘awareness’ was carried out in December 2011. The detailed search strategy for PubMed can be 
found in Appendix 8.1. This was adapted according to syntax and MeSH terms for other 
databases. Sixteen electronic databases were searched including: Medline and Medline in 
Process & Other Non-Indexed citations; Embase; Cochrane Library comprising the Cochrane 
Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Health 
Economic Evaluation Database, Health Technology Assessment Database, Database of 
Abstracts of Review of Effects; Web of Science Citation Index, Social Science Citation Index and 
the Conference Proceedings index; CINAHL; PsycINFO; HMIC; Social Policy and Practice; and 
Dissertation Abstracts. Searches were limited to English language only.  
 
For ongoing and unpublished research, the following sources were searched: UK CRN Portfolio 
Database; Clinical Trials.gov; Open Grey; American Society of Cancer Oncology; and European 
Society for Medical Oncology. International cancer registries were also searched using ‘bowel 
cancer awareness’ or ‘awareness’ terms: the United Kingdom Association of Cancer Registries; 
the Australasian Association of Cancer Registries; the European Network of Cancer Registries; 
and the North American Association of Central Cancer Registries. 
 
Studies were excluded from the review on the basis of their title or abstract and included with 
reference to the full text article. Inclusion and exclusion criteria were developed and are provided 
in detail in Appendix 8.2. These included: 
 
• Population: Include populations not selected on the basis of familial/historical risk or 
compliance with screening recommendations (as such interventions would require a 
resource-heavy screening stage and would not provide efficacy data relating to campaigns 
delivered to whole populations). Studies which selected discrete sub-populations, such as a 
BME population within the wider general population, were included.  
• Intervention: Campaigns aiming to raise awareness and promote early presentation, or 
campaigns aiming to promote screening compliance and increase early detection. Resource-
heavy interventions which relied on one-on-one attention were not included as these were not 
deliverable to a whole population. 
• Comparator: Any or no comparator was acceptable. 
• Outcomes: One or more of the following outcomes: campaign awareness, change in 
knowledge or beliefs relating to CRC or CRC screening, numbers of GP visits, number 
screened, referrals, diagnoses, time to diagnoses, stage at presentation and 
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survival/mortality. Studies which recorded outcomes on the same day that the intervention 
was delivered (usually relating to attitude or knowledge) were not included, as this was not 
thought to give a reliable indication of long-term effects. 
Items relating to study design, population, intervention, comparator and outcomes were extracted 
by one reviewer (SH or ES) into a piloted, standardised data extraction form in Excel. Quality 
assessment was performed by one reviewer (SH) using criteria adapted from the CASP tool for 
cohort studies,[6] the Downs and Black criteria for non-randomised studies[7] and the Newcastle 
Ottawa Scales for cohort and case-control studies[8] arranged under the risk of bias domains 
described in the Cochrane Handbook,[9] namely: selection bias, performance bias, detection bias, 
attrition bias and reporting bias. An additional item on confounding was included for uncontrolled 
studies. The rubric for scoring is provided in Appendix 8.3.   
A narrative review was used to summarise the included studies. A meta-analysis was planned 
where data was allowing, but heterogeneity of study variables prevented this.  
As a large number of studies narrowly missed the inclusion criteria (being included on the basis of 
their abstract, but being excluded on the basis of the full text article) but appeared to be of some 
interest to the review question, an ad hoc mapping analysis was performed to provide a wider 
overview of the types of interventions which may be effective. Key study variables were extracted 
and coded by one reviewer. Variables were classed as relating to “how” the intervention was 
delivered (to the population, groups or individuals, via which resources), or to “what” was 
included, and represented visually. Results were extracted as either showing a significant 
improvement or showing a non-significant improvement or negative result. The magnitude of 
effect was not extracted, and studies were not subject to quality assessment. In addition, it should 
be noted that as this mapping review is a by-product of the wider review, it should not be relied 
upon as systematic or comprehensive; studies may have been excluded at the abstract stage that 
could have been included. However, it is unlikely that selection bias has occurred as a result of 
this, and the sample is likely to be proportionally representative of the full body of literature 
available, and the wide range of approaches that have been implemented in promoting early 
presentation of CRC. 
 
2.4. Results 
The systematic literature search identified 2,897 titles, of which 95 abstracts were included, with 
an additional five abstracts included from grey literature sources or hand sifting. The selection 
process is summarised in the PRISMA flow chart[10] in Appendix 8.4. Eleven studies met all the 
inclusion criteria and were included in the systematic review. Studies which were included on the 
basis of their abstract, but excluded from the final review, are listed in Appendix 8.5.  Of these, 56 
described interventions which the review team felt may be of interest, even though they did not 
meet the inclusion criteria. These are summarised in the mapping review.  
  
2.4.1 Systematic review results  
 
Study characteristics 
 
Eleven studies were included in the review (Table 1).[11-21] One was a randomised 
controlled trial (RCT), [11] four were non-randomised controlled trials [12,15-17] and 
the remaining six studies were before-after studies or interrupted time 
series.[13,14,18-21]  Most studies took place in the USA, with three studies in the UK 
[12-14] and another in Holland.[11] Four studies targeted or reported on communities 
with a black or minority ethnic (BME) identity (Vietnamese Americans; [15] African 
Americans;[16,17] and Hispanic men).[21] Three studies targeted low income 
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areas,[13,18,20] one of which targeted women in a predominantly African American 
community,[18] and one of which was an area with low screening rates.[20] Two 
studies targeted older adults,[12,19] one targeted older men,[14] and one targeted all 
adults.[11]  
 
 
Table 1  Study characteristics 
 
Study Study 
Design 
Country Dates N Centres N  Population 
Aim to increase self-presentation 
de Nooijer 
2004[11] 
RCT  Holland 1999 National 1,358 Adults (excluded cancer patients) 
WoSCAP[12] NRCT & 
BA, IS 
Scotland 2004 Regional NRCT:  
583 (Int) 
351 (C) 
Adults over 50 
Lyon 2009[13] BA* England 
 
2007 to 
‘09 
111 practices 
(10 areas) 
630,000 Disadvantaged areas (spearhead 
PCTs) 
Ramsay, date 
NR[14] 
BA, IS England 2010 Regional 300 (B) 
300 (A) 
Men over 50 
Aim to increase screening attendance 
Blumenthal 
2005[16] 
NRCT, IS USA  1994 to 
‘96 
4 Regions 4,053(B)  
3,914 (A) 
 African Americans  
Nguyen 2010[15] NRCT USA 2004 to 
‘07  
Regional 894 (B) 
533 (A) 
Vietnamese Americans; medical 
staff 
Powe 2004[17] NRCT USA 
 
NR 15 senior 
citizen centres 
134 Older adults, predominantly 
African Americans 
Katz 2007[18] ITS, IS 
 
USA 
 
2000 to 
‘03 
11 cities (4 
regions) 
2,098 Women, subsidised/low-income 
housing, mostly African American 
Broadwater 
2004[22] 
BA, IS USA 2003 Regional 409 (B) 
403 (A) 
Older adults 
Katz 2011[20] BA, IS USA 2007  Regional 170 (B) 
61 (A) 
Low-income area with high 
incidence and low screening 
rates. 
Zhou 2011[21] BA, IS** USA 
 
1999 to 
‘05 
Regional 4,048 (B) 
4,285 (A) 
Hispanic and white non-Hispanic 
men  
*Interim results - project dissolved when Improvement Foundation ceased trading. 
** Before data recorded one year after campaign started 
BA, before-after study; IS, independent sample where the before sample comprised different individuals than the after 
sample; RCT, randomised controlled trial; NRCT, non-randomised controlled trial; ITS, interrupted time series; B, before; A, 
after; Int, intervention; C, control 
 
Quality assessment 
Overall, the quality of the body of evidence comprising this review is at best moderately good, at 
worst, poor, but remains to a significant extent, unknown. As most studies are either observational or 
non-randomised, even if studies were to score well on every quality assessment item, there would 
remain limitations to the data within this review.   
A summary of the quality assessment of studies is presented in Figure 2. No study scored well for 
every item, and no item scored well in every case. Zhou et al[21] scored best overall, but was at risk 
of confounding and selection bias. Amongst non-randomised trials, before-after studies and 
interrupted time series studies, many did not provide enough information to enable assessment of risk 
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of bias. Notably, data for two studies from the UK[12,14] were only available as unpublished data from 
online sources, and information relating to risk of bias was not reported in either case. Most studies 
selected their participants in a way that had a low risk of bias. However, information relating to 
comparativeness of the two arms, or the before and after cohorts was not provided or scored 
negatively, meaning the risk of selection bias affecting the results is unknown, but potentially high. 
Likewise, the blinding of participants was poorly reported and only one study clearly avoided detection 
bias, meaning that there is a potentially high risk of performance and detection bias affecting the 
results. For the six before-after and interrupted time series studies, confounding was only adequately 
dealt with by one study. There is therefore a high risk that the results of this review are subject to 
confounding. 
The one RCT, de Nooijer et al,[11] scored unclear or negative for most items and is therefore of 
unknown quality.  
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Figure 2 Risk of bias summary: review authors' judgements about each risk of bias item for 
each included study, scored according to study design. Marking rubric can be found 
in Appendix 8.3. 
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Interventions to increase early detection of CRC 
A description of the interventions is provided in Table 2. 
Aim of intervention. Four interventions [11-14] aimed to increase self-presentation. All appeared to 
include a description of symptoms to look out for (detail from de Nooijer et al[11] is vague). Other 
studies aimed to increase screening rates: whilst it was not clear what message was given about 
symptoms in all cases, in at least one case (Broadwater et al)[22] the message was that CRC has no 
early warning signs, and screening was therefore necessary. Six interventions targeted CRC alone, 
whilst five assessed campaigns which included at least one other cancer in the same study. It was not 
always clear if there were separate materials for each cancer in these campaigns, although this 
appeared likely in most cases. 
Target population. Four interventions targeted the general population or older adults in the general 
population. One included the use of an information leaflet (this study also tested a tailored letter, 
which did not meet the inclusion criteria for this review) (de Nooijer et al)[11], whilst the other three 
were complex interventions with multiple components and outlets including (variously) TV, radio, print 
materials, comedy shows, photo exhibitions and so on (see Table 2).[12,14,19] One intervention also 
included a television broadcast of a live colonoscopy.[19]  
i. Non-randomised controlled trials, 
interrupted time series and before-after 
studies 
 
ii. Randomised controlled trial study design 
 
+, low risk of bias; -, high risk of bias; ?, 
unknown risk of bias; blank, not applicable. 
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Interventions aimed at BME populations used a variety of means to reach the target group, including 
an innovative community-led approach where interventions were devised and delivered by members 
of the community (Blumenthal et al)[16]; a programme which reached Vietnamese Americans through 
Vietnamese language outlets including TV, radio and newspapers, as well as through local 
businesses and at community events (Nguyen et al);[15] a national programme which incorporated a 
bilingual component to target Hispanic Americans (Zhou et al);[21] and a culturally relevant 
intervention which included a Christian faith message for a community which was predominantly 
African American (Powe et al).[17]  
One of the interventions aimed at disadvantaged areas also employed a community-based approach 
where members of the local community were involved in devising and delivering the interventions in a 
wide range of venues and in very creative ways.[13] The two remaining interventions were targeted at 
disadvantaged areas engaged in community consultation to inform the design of more appropriate 
interventions which aimed to address barriers and be culturally acceptable.  
Design of interventions. Most interventions were designed with some degree of consultation with the 
community. These included: 
• Baseline surveys or focus groups to establish needs in terms of current levels of knowledge, 
prevalent attitudes, behaviours and cultural norms, e.g. Broadwater et al.[19]  
• Focus groups to comment on material designed by research team, e.g. WoSCAP[12] 
• Engaging the community in the design and delivery of the intervention from the outset.[13,16] 
However, in some cases the design method was not clear or only researchers or healthcare 
professionals were involved.  
Duration of intervention. Interventions ranged in length from simply watching a video or reading a 
leaflet, to concerted campaigns over several years (see Table 2 for details). 
 
Outcomes 
 
The results reported by the included studies are summarised in Table 3. Only direction of effect and 
statistical significance has been included in this summary, with final value data provided for screening 
rates to allow comparison to other known screening rates.  
 
Aim of intervention. Of the four studies[11-14] which aimed to increase early presentation or 
detection, only one[13] reported adequate data on outcomes towards the end of the logic model. This 
study showed an increase in urgent referrals, and whilst this resulted in an increase in diagnoses 
through the urgent referral route, there was only a non-significant increase in the number of early-
stage diagnoses. However, the outcome in this study was dichotomised to early presentation 
(presentation with no nodal or distal metastases) or non-early presentation. It is possible that whilst 
statistically significantly more cancers were not detected in the early stage, a shift towards 
presentation at an earlier stage (e.g. only one nodal metastases rather than several) may have been 
achieved. Data on exact stage at presentation was not available from this study. 
 
De Nooijer et al[11] concentrated on outcomes at the earlier stage of the logic model. For De Nooijer 
et al[11], there were proportionately more participants who reported an increase in knowledge and a 
change in their intentions in the intervention arm at T1, but this effect was not reported and not 
maintained at T2 respectively. 
 
WoSCAP[12] reported increases throughout the logic model, but no statistical significance tests were 
reported for any of the results. Similarly, Ramsay[14] reported improvements throughout most of the 
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logic model, though consultation numbers appeared to fall. Again, the statistical significance of these 
results was not reported.  
 
Target population. The data do not suggest any trend towards a greater or lesser likelihood of an 
intervention effect being statistically significant depending on which group it is targeted at. 
Interventions which targeted distinct subpopulations generally appeared to have some degree of 
success in reaching these previously underserved groups. However, whether the magnitude of the 
change brings these groups in line with population norms is unclear, except in the study reported by 
Zhou et al,[21] whereby the increase in screening amongst Hispanics did not bring rates in line with 
white non-Hispanics. 
 
Community involvement. The two studies which engaged communities in the development and 
delivery of materials showed predominantly positive outcomes, though neither recorded the same 
outcomes. Blumenthal et al[16] reported statistically significant increases in screening rates in one 
area, but not in the other. Awareness of the campaign also varied by component and area. As already 
summarised, Lyon et al[13] reported a significant increase in diagnoses via urgent referrals, but only a 
non-significant increase in early-stage presentation.  
 
Multiple cancers targeted. Of the four studies[15,17,18,20] which targeted CRC alone, three[15,17,18] 
reported results for screening uptake. All reported increases, but some outcomes did not reach 
statistical significance. Of the five studies which assessed campaigns targeting multiple 
cancers,[11,13,16,21,22] significant increases in screening were reported on three 
occasions,[13,16,21] though in one case[13] there was also a non-significant decrease in screening 
rates. 
 
Coherence with logic model. In general, the logic model appeared to be supported by the available 
evidence, regardless of the target population and other heterogeneous study characteristics. Whilst 
most studies reported a mix of statistically significant and non-significant results, trends were in nearly 
all cases (apart from the Nashville screening rates outcome reported in Blumenthal et al[16] and 
consultation numbers reported in Ramsay[14]) consistent with the pathway. Nguyen et al[15] reported 
the most complete pathway, but fell short of reporting the number of diagnoses. Similarly, 
WoSCAP[12] reported a number of stages in the pathway, with changes coherent with the logic 
model, but did not report statistical significance of the changes. However, none of the studies reported 
long-term results for mortality and morbidity. The furthest point in the model is provided by Lyon et al 
[13], which only reports a non-significant improvement in diagnosing CRC before it has spread. As 
such, the final and crucial steps in the pathway are left under-informed or not supported. 
 
Meta-analysis. A meta-analysis was not appropriate given the marked heterogeneity in all study 
variables. 
Duration of effect. Only three studies aimed to record outcomes at more than one time-point. Attitudes 
were significantly improved at 3 months, but not maintained at 6 months after viewing a leaflet, 
compared to usual care in de Nooijer et al[11]. No data were available from the other two studies, as 
the first time-point was not reported by Lyon et al[13], and the intervention was still being delivered 
during all three time-points reported by Powe et al[17] for one intervention arm, whilst the other 
intervention arm (for whom intervention delivery only involved viewing a video once) was not reported 
at the interim time-point.  
Two studies reported outcomes at more than one year (Nguyen et al and Zhou et al).[15,21] However, 
for both, the intervention was still being delivered at the time-point, and the data cannot be used to 
inform the duration of the effect of the intervention.  
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2.4.2 Mapping review results 
 
The mapping review collated and categorised the components of the interventions that have been 
used to increase early detection of CRC, along with a top-level indication of reported estimates of 
efficacy (Figure 3). 
 
Fifty-six studies excluded at full text reported interventions which are of relevance to the review 
question, regardless of the reasons for exclusion. Of the excluded studies: 22 were excluded because 
patients were selected on the basis of risk due to either not being up to date with screening, or due to 
family or personal history; two were excluded because they were published as an abstract only; one 
described the intervention, but provided no results; six because the intervention included one-to-one 
attention; 15 because the outcome was recorded on the same day as the intervention; four because 
they were published as theses; one because it was a staff intervention with no data on patient 
outcomes; and five because the study had an inappropriate study design.  
 
Items relating to “how” an item was delivered are mapped in the lower half of Figure 3. Culturally 
relevant interventions included using bilingual patient navigators (who help patients make 
appointments, arrange travel, fill in forms, etc.), using images of people of the relevant ethnicity, using 
community establishments such as churches to reach people and using healthcare staff or lay 
volunteers of the same ethnicity to deliver the intervention. Filmed interventions were delivered via 
TV, radio, WebPages, projected during presentations, or played on DVD/video players. Electronic 
devices included portable DVD players, laptops, screens in doctors’ waiting rooms, PowerPoint 
presentations, audience response systems and interactive computer programmes which delivered 
tailored messages. Literature included brochures, leaflets, pamphlets, and letters.  
 
Items relating to the content of the interventions (“what”) were coded and are mapped in the upper 
half of Figure 3. Messages about signs and symptoms varied from stating that there are no early 
warning signs and therefore screening is the best way to detect CRC early, to listing various signs, 
such as bleeding from the rectum, or having unusual bowel movements for more than a certain 
number of weeks, that mean you should visit a doctor. Some studies included a demonstration of how 
to complete an FOBT test. Such demonstrations included films shown to groups, where a nurse used 
peanut butter or play dough to demonstrate, as well as demonstrations given one-to-one. Instructions 
were usually written, sometimes with diagrams for those with low literacy. Risk messages included 
increased risk for Asians now living in America, increased risk due to age and family or personal 
history, and increased risk from lifestyle factors. Assessment and help with barriers was often 
performed via the telephone or in one-to-one and small group sessions. In some cases, this was 
automated by a computer programme, or involved an algorithm which was followed by telephone 
staff.   
 
The number of studies for each item which reported a significant result shows that most components 
of the interventions appear to be associated with positive outcomes. However, nearly all interventions 
comprised several approaches, so it is not possible to ascertain which aspects conferred a positive 
effect. One association of interest is that decision aids (which aim to help people make a decision 
about whether to have screening, or which screening mode to opt for) did not appear to be associated 
with positive improvements in screening numbers or attitudes and intentions towards screening. As 
with the results of the main review, the data to inform the final step in the logic model, between an 
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increase in screening rates and an increase in detection or stage at detection, is not well informed by 
this mapping review. 
 
 
2.4.3 Data for use in the model 
Several studies with the potential to contain data to inform the cost-effectiveness modelling were 
identified by the systematic review. However, none of them provided enough data to be useful. The 
study of most relevance and with the most complete data-set was the study reported by Lyon et al. 
[13] As described above, this study was based in the UK and reported outcomes for urgent referrals 
and proportion presenting with early stage CRC. However, the cost-effectiveness of this targeted 
campaign could not be evaluated as sufficient information on effectiveness and costs of the campaign 
was not available. 
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Figure 3 Map of variables relating to design of interventions and number of studies reporting positive results 
 
* Not coded separately. Stage of readiness = readiness to attend screening; Barriers = barriers to attending screening. 
Variable with number of interventions using it in brackets, followed by number of studies reporting a statistically significant result over the number of studies reporting any result 
for the variable, for the outcomes K (knowledge), A (intentions or attitude), S (number screened) and D (number of polyps or cancers detected).
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 3. Bowel Cancer Signs and Symptoms Campaign 
 
In addition to the studies identified by the systematic review, data was available via the Department of 
Health relating to a pilot awareness campaign in England. The data was provided in a report 
produced for the Department of Health: ‘Evaluation of the Bowel Cancer Awareness Pilot…’ and more 
recent data on cancer incidence were also obtained from the South West Public Health Observatory 
(SWPHO) and the Eastern Cancer Registration and Information Centre (ECRIC).[4,23,24] This 
section describes and analyses this data. 
 
3.1. Campaign overview 
A bowel cancer signs and symptoms campaign was piloted in two regions (the East of England and 
the South West) by the Department of Health in January 2011. The aim of the campaign was to 
increase awareness of the signs and symptoms of bowel cancer and to encourage persons with 
symptoms to visit their GP. The campaign message was: “If you have (1) A persistent change in 
normal bowel habit, such as going to the toilet more often and diarrhoea, especially if you are also 
bleeding from your back passage, or (2) Bleeding from the back passage without any reason, 
particularly over the age of 55, then it’s important to go and see your GP. The sooner you see your 
doctor to have it checked, the better.” The total population of the two pilot regions was approximately 
11 million persons. The pilot campaign was delivered for seven weeks (24th January - 21st March 
2011) via the following channels: regional TV, print media (regional/local press etc.), inserts into 
regional editions of national press, online, regional/local radio, and shopping centres. A bowel cancer 
resource pack was sent to GPs and this contained detailed information for each local authority. 
Although the message mentioned “over the age of 55”, the campaign will have reached persons of all 
ages. Following the pilot a national campaign was run starting in January 2012. 
 
Monitoring of the pilot campaign included: collection of data on incidence through Cancer Registries, 
data on referrals from Cancer Wait times, data on screening uptake from the NHS cancer screening, 
a survey of GP attendances undertaken by Mayden Health, and exit interviews at shopping centres to 
determine the reach of the advertising.[4,23-29] Data from the pilot campaign monitoring were used to 
inform the cost-effectiveness model. We present our analysis of the pilot campaign data here, 
including: changes in GP attendances, secondary care appointments, CRC incidence, screening 
uptake and campaign running costs.  
 
 
3.2. GP attendances 
Data on GP attendances associated with CRC symptoms were collected from a sample of 74 
practices. The included practices were spread across three cancer networks and, for the purpose of 
this analysis, data from the three networks were grouped together (the Anglia network, the Avon, 
Somerset and Wiltshire network (ASWCN) and the part of the Mount Vernon Cancer network covered 
by the TV campaign). Data were collected on GP attendances prior to the campaign (January 2010 - 
January 2011), during the campaign (February-March 2011), and for one month following the 
campaign (April 2011). The data used here considers GP attendances associated with the three 
symptoms which directly relate to the campaign (rectal bleed, loose stools, and change in bowel 
habit) or diarrhoea. Diarrhoea was not specifically mentioned in the campaign but was included as it is 
so closely related to change in bowel habit and loose stools.  
 
The data on GP attendances from the pre-campaign period (January 2010 - January 2011) displayed 
considerable monthly variation; see Figure 4. To reduce the impact of these monthly variations we 
compared average monthly attendances from the periods February 2010 – April 2010 and February 
2011 – April 2011. (The original analysis adjusted by working days per month but as data were 
averaged over three months this was deemed unnecessary.) A summary of the GP attendance data 
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related to the campaign is shown in Table 2. Two analyses were undertaken: with and without 
diarrhoea included as a symptom. The number of GP attendances in the sample of practices 
increased by approximately 700 during the period February-April 2011 which would correspond to an 
increase of approximately 80,000 on a national scale - a 62% increase for the 3-month period. The 
increase was slightly less (around 60,000) when diarrhoea was included as a symptom. The available 
data provide no information on the duration of the increase in GP attendances as no data were 
collected for GP attendances following April 2011.  
 
Although the target population for the campaign was persons aged over 55, the nature of the 
campaign meant that persons of all ages were exposed. The data analysis did not demonstrate a 
change in the gender or age distribution of patients as a result of the campaign. 
 
The change in GP attendances caused by the campaign is associated with considerable uncertainty 
due to large variations between practices and a possible change in symptom coding between 2010 
and 2011. 
 
Figure 4:  GP attendances associated with CRC symptoms 
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Table 2:  GP attendances associated with CRC symptoms  
Rectal bleed, loose 
stools, and change 
in bowel habit
Rectal bleed, loose 
stools, change in 
bowel habit or 
diarrhoea
GP attendances during the 3 month period Feb-Apr
2010 1127 2685
2011 1827 3217
% increase 62% 20%
Increase in GP attendances Sample 700 532
England 79,645                  60,595                   
 
 
 
3.3. GP referrals/Secondary care appointments 
Data on the number of 2-week wait referrals from GP to secondary care with suspicion of lower 
gastrointestinal cancer were available for the East of England for the period 1st February to 30th June 
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for both 2010 and 2011. A 28% increase in referrals was seen from 2010 to 2011 which corresponds 
to approximately 17,000 additional referrals on a national level; see Table 3. The data suggest that 
the campaign had a significant effect on the number of GP referrals during the latter half of the 
campaign and during the 6 weeks following the campaign; see Figure 5. However, without data for the 
period after June 2011 it is not possible to be sure of the duration of the effect of the campaign. 
 
There was also evidence of an increase in colonoscopy demand and activity during the period 
February-June 2011 when compared to the previous year. 
 
Table 3:  Referrals from primary care for suspected lower GI cancer 
Referrals from GP to secondary care for suspected lower gastrointestinal cancer
Referrals during 5 month period 1 Feb - 30 Jun 2010 6967
2011 8923
increase 1956
increase scaled up to England population 17,519                          
% increase 28%  
 
Figure 5:  Referrals from primary care for suspected lower GI cancer 
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3.4. Cancer incidence 
Data on monthly CRC incidence for the East of England and South West regions combined were 
available for the period January 2010 – September 2011, see Table 4 and Figure 6. There is a 
significant lag between a cancer diagnosis and a registry receiving information on a cancer diagnosis; 
referred to as ‘reporting delay’. Cancer incidence data can usually be adjusted for reporting delay to 
account for anticipated future corrections to registry data due to inherent delays and errors in case 
reporting.[30] Due to changes in reporting methods during 2011, a precise reporting delay adjustment 
was not possible. However, the data used here was obtained from the Cancer Registries in October 
2012 hence should be reasonably complete and not significantly biased by ‘reporting delay’. 
 
   
As the campaign started at the end of January 2011 it was assumed that a change in the incidence 
would not be expected until March 2011. A t-test was undertaken to see if the cancer incidence 
observed in March 2011 was statistically significantly different compared to the proceeding period 
(January 2010 - February 2011). The pooled data set and the East of England data set had p-values 
of less than 0.005 suggesting that an increase did occur in March 2011. When looking just at the 
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South-West data set the increase was less significant with a p-value of 0.109. No significant increase 
in incidence was observed for the period April 2011 onwards, considering a p-value of 0.01. We 
conclude that any increase in incidence caused by the pilot campaign was not sustained. 
 
Table: Results of t-test comparing March 2011 to the period January 2010 - February 2011 
Two-tailed p-value
Pooled SW and EoE 0.002
South West 0.109
East of England 0.001  
 
 
Although an increase in incidence was observed in March 2011 there is considerable uncertainty 
surrounding whether this increase was in fact due to the pilot campaign. Monthly variations may occur 
as a result of factors such as: different length months, different numbers of clinics, different numbers 
of working days, etc. Another possible limitation is the assumption that similar incidence would be 
expected in 2010 and 2011. A comparison of 2010 and 2011 incidence data from regions not 
participating in the pilot may clarify whether this assumption is indeed reasonable; however such data 
was not available. We conclude that the pilot campaign may have led to a small increase in incidence 
for a short period (1 month) following the campaign. The incidence for March 2011 was 11% higher 
than that seen in March 2010 and 7% higher than the mean+2sd for the period January 2012 to 
January 2011. So the modelling will assume that the pilot campaign may have led to an increase in 
incidence of 7-11% for a period of 1 month only. 
 
Note that this incidence includes screen-detected incidence as data were not available from the 
cancer registries on diagnosis route (i.e. whether the patient self-presented to a GP due to symptoms, 
completed a routine screening test, emergency presentation, etc.). In 2010, screen-detected 
incidence accounted for approximately 10% of the total CRC incidence in the pilot regions. Data on 
screen-detected CRC did not show any relationship with the awareness campaign.[27] It should be 
noted that screen-detected incidence may differ slightly to the CRC incidence reported by the cancer 
registries due to potentially different classifications e.g. differences in whether secondary colorectal 
tumours are classified as CRC. Assuming that the increase of 7-11% observed does not relate to 
screen detected cases, it follows that the increase in symptomatic-detected incidence would be 8-
12%. Hence the base case analysis considers an increase in symptomatic-detected incidence of 
10%. 
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Table 4: CRC incidence in the East of England and South West regions combined (data extract date 
October 2012) 
Month South West
East of 
England
Pooled SW 
& EoE
Jan-10 316 347 663
Feb-10 297 305 602
Mar-10 323 362 685
Apr-10 338 354 692
May-10 319 345 664
Jun-10 313 345 658
Jul-10 317 330 647
Aug-10 307 351 658
Sep-10 347 320 667
Oct-10 300 360 660
Nov-10 298 354 652
Dec-10 267 330 597
Jan-11 295 327 622
Feb-11 297 331 628
Mar-11 345 416 761
Apr-11 311 316 627
May-11 310 341 651
Jun-11 318 403 721
Jul-11 299 335 634
Aug-11 283 358 641
Sep-11 313 323 636
Oct-11 281
Nov-11 317
Dec-11 288   
 
Figure 6: CRC incidence in the East of England and South West regions combined (data extract 
October 
2012)
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3.5. Cancer incidence by stage 
Data on CRC incidence by stage was available for the period January 2010 – December 2011. A 
summary of the data is presented in Table 5. For the South West region there was a slight decrease 
in the proportion of stage D CRC and a slightly higher proportion unstaged for the post campaign 
period. Note that the data have not been pooled as different staging classifications were reported for 
the different regions. Generally the numbers of cases by stage are too small for the pilot regions to be 
able to reach any significant conclusions on changes to the stage distribution. This is illustrated by the 
confidence intervals presented in Table 5. 
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Table 5: Colorectal cancer incidence by Dukes’ 
stage
East of England
Before Pilot After Pilot
Integrated clinical stage Count Proportion and CI Count Proportion and CI
In situ 745 0.15  (0.14, 0.16) 403 0.16  (0.15, 0.18)
1 719 0.15  (0.14, 0.16) 339 0.14  (0.12, 0.15)
2 997 0.21  (0.19, 0.22) 465 0.19  (0.17, 0.20)
3 988 0.20  (0.19, 0.22) 481 0.20  (0.18, 0.21)
4 820 0.17  (0.16, 0.18) 446 0.18  (0.17, 0.20)
Stage not known 567 0.12  (0.11, 0.13) 322 0.13  (0.12, 0.14)
Total 4836 2456
South West Region
Jan 2010-Feb 2011 March -Dec 2011
Count Proportion and CI Count Proportion and CI
A 593 0.14  (0.13, 0.15) 475 0.15  (0.14, 0.17)
B 1249 0.29  (0.27, 0.30) 876 0.29  (0.27, 0.30)
C 1134 0.26  (0.25, 0.27) 844 0.28  (0.26, 0.29)
D 872 0.20  (0.19, 0.21) 411 0.13  (0.12, 0.15)
Invalid/ Unknown 486 0.11  (0.10, 0.12) 459 0.15  (0.14, 0.16)
Total 4334 3065  
 
 
3.6. Screening uptake 
The Bowel Cancer Screening Programme (BCSP) in England offers biennial screening to all persons 
aged 60-74 with the guaiac faecal occult blood test (gFOBT). Screening started between 2006 and 
2010 depending on region. Data on uptake at screening during the period January 2010 – November 
2011 were available from the BCSP for the two regions covered by the pilot.[27] Variations in uptake 
are complex to understand as overall uptake can be confounded by other factors such as the 
screening round (prevalent/incident) and episode number. For example, low levels of overall uptake 
were observed in 2011 but these are due to a decrease in invites of type “prevalent episode 1” 
(persons not previously screened and invited for the first time - average uptake 57%) and an increase 
in invites of type “prevalent episode 2” (persons not previously screened and invited for second time - 
average uptake 23%); see Table 6. 
 
An increase in overall uptake was observed during the campaign period, however, further data 
analysis suggests this may not be due to the campaign. An examination of the uptake graphs for the 
three subgroups: prevalent episode 1, prevalent episode 2, and incident episode 2+, demonstrated 
that only the subgroup ‘prevalent episode 1’ showed a significant increase. However, this increase 
occurred from December 2010 - March 2011 so cannot be attributed to the campaign. To conclude, 
the screening data do not demonstrate a significant increase in uptake during/following the awareness 
campaign period.  
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Table 6: Summary of screening uptake data 
Subgroup Invited Adequately screened Uptake
2010 (Jan-Dec)
Prevalent episode 1 248042 65% 138621 56%
Prevalent episode 2 49124 13% 11059 23%
Incident episode 2+ 85059 22% 75559 89%
Other 134 0% 79 59%
All persons 382359 100% 225318 59%
2011 (Jan-Nov)
Prevalent episode 1 113862 33% 65223 57%
Prevalent episode 2 98837 29% 21791 22%
Incident episode 2+ 127254 37% 112722 89%
Other 5857 2% 822 14%
All persons 345810 100% 200558 58%  
 
 
Figure 7: Screening uptake for the SW and EoE regions combined 
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3.7. Awareness campaign costs 
The total cost of running the pilot awareness campaigns in the East and South West of England was 
provided by the Department of Health. The total cost was £1,586,000 which is equivalent to £0.22 per 
person living in the region aged 30 or over. The components of this cost are detailed in Table 7. The 
budgeted spend for the national campaign in 2012 was £4.5 million, which is equivalent to £0.14 per 
person aged 30 or over. 
 
Table 7 Bowel Cancer ‘Signs and symptoms’ campaign costs 
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Pilot Campaign Breakdown of costs Actual cost
Delivery: Advertising Media, Events etc £845,000
TV £213,000
Radio £76,000
Regional press £240,000
Face to face events £103,000
Paid for search (online advertisement) £21,000
Other (includes partnership costs, fulfillment/deliver costs for leaflets and posters £65,000
DRM (including inserts in newspapers, service to put leaflets in GP surgeries) £127,000
Research and evaluation £181,000
Creative development (costs of producing adverts and other materials) £540,000
Other (includes strategy/planning costs and other miscellaneous costs) £20,000
TOTAL £1,586,000
Pilot Campaign 31st Jan-13th Mar 2011 Actual cost
Total cost £1,586,000
Total population in East and South west of England aged 30+ 7,148,045        
Cost per person aged 30+ £0.22
Bowel cancer campaign NATIONAL Feb-Mar 2012 Budgeted cost
Total cost £4,500,000
England population aged 30+ 32,621,167
Cost per person aged 30+ £0.14   
 
 
 
4. Cost-Effectiveness Methods 
 
4.1. Modelling Overview 
The model used here is an adaptation of a model used to assess the cost-effectiveness of various 
options for CRC screening.[31] The original model consisted of two components: the first describes 
the natural history of CRC by representing the development of adenomas and their progression to 
CRC, and the second describes the effect of screening and surveillance. This adaptation of the model 
also incorporates the costs and benefits of an awareness campaign. The analysis captures the direct 
costs of the campaign, the costs of any additional GP consultations/appointments in secondary care 
resulting from the campaign, and the benefits of the campaign resulting from earlier diagnosis or a 
change in screening uptake. 
 
The modelling assumes that the awareness campaign results in a change in the probability of a 
person with undiagnosed CRC presenting symptomatically at their GP. This change in the 
symptomatic presentation probabilities is determined so that model predictions of change in CRC 
incidence reflect those seen following the pilot campaign. The model responds to these adjusted 
symptomatic presentation probabilities by predicting associated changes in time to diagnosis, stage of 
diagnosis and CRC mortality due to the campaign. Additional costs associated with GP attendances 
and referrals are modelled based on the data from the pilot. 
 
The comparator used for the modelling is no early awareness campaign and this baseline includes 
the current screening programme of biennial gFOBT.  A one-off awareness campaign and a repeated 
annual awareness campaign are both evaluated as potential interventions. The natural history 
component of the model simulates development of adenomas and CRC and death for a cohort of 
individuals. The general population of England was modelled as a series of such cohorts. Each cohort 
is offered CRC screening and is exposed to the signs and symptoms campaign. Total costs and 
quality-adjusted life years (QALYs) accrued by the population were calculated. 
 
The model takes the perspective of the NHS and a discount rate of 3.5% per annum was applied to 
costs and QALYs in line with current NICE recommendations.[32] Estimates of changes in expected 
costs, QALYs, resource use, CRC incidence and CRC mortality associated with the awareness 
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campaign were produced. The net monetary benefit (NMB) of each intervention was calculated 
assuming a willingness-to-pay threshold of £20,000 per QALY gained. In health economic terms, a 
strategy associated with a greater NMB is preferred. Incremental cost effectiveness ratios (ICERs) 
were evaluated compared to ‘no early awareness intervention’.  
 
The potential effects of an early awareness campaign are summarised in Figure 8. 
 
Figure 8: Summary of potential effects of an early awareness campaign 
 
 
 
Studies used to inform the evaluation  
Several studies with the potential to contain data to inform the cost-effectiveness modelling were 
identified by the systematic review (see Chapter 2). However, the only study which collected data on 
changes in CRC incidence due to the campaign (essential for the modelling) was the unpublished 
data from the pilot signs and symptoms.[25-29] 
 
 
4.2. CRC natural history model and model calibration 
A detailed description of the CRC natural history model and model calibration approach used are 
available in the report “Reappraisal of the options for CRC screening”.[31] We will provide a brief 
overview of the methods here. 
 
A state transition model was used to simulate the life experience of a cohort of individuals in the 
general population of England. All persons are assumed to have a normal epithelium at age 30 and 
may then develop adenomatous polyps and malignant carcinoma and subsequently die. The health 
states are defined as normal epithelium, low risk (LR) adenomas, high risk (HR) adenomas, 
preclinical CRC Dukes’ stages A-D, clinical CRC Dukes’ stages A-D, and dead. (We use preclinical to 
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refer to the cases when CRC has developed but not yet been diagnosed.) The health states and 
transitions included within the natural history model are illustrated in Figure 9. We refer to the 
transition probabilities between the modelled health states (e.g. the probability of moving from HR 
adenomas to Dukes’ A CRC) as the CRC natural history model parameters. The natural history model 
structure assumes that the rates of transition from preclinical to clinical CRC do not vary by age. 
 
Figure 9: Diagram of colorectal cancer natural history model structure and screening pathways 
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Several data sets were used to inform the model parameters through a process of model calibration. 
Data on CRC incidence in the absence of screening categorised by age and Dukes’ stage at 
diagnosis were taken from England cancer registry data for Oxford, Northern and Yorkshire, and 
Eastern regions from 2004 – 2006.[33] The CRC survival data used within the model were updated 
for this project using survival by age and stage at diagnosis from the ICBP; full details are provided 
within the Appendix 8.6.[34] Data from several screening programmes were also used within the 
calibration process. The current gFOBT BCSP in England reported numbers of persons with positive 
gFOBT results and the detection rates of low and high risk adenomas and CRC at screening.[35] 
Data from the flexible sigmoisoscopy (FS) trial consisted of detection rates of CRC, low/high risk 
adenomas and non-advanced/advanced adenomas at screening.[36] As UK data are only available 
for gFOBT and FS, screening test data from the Italian immunochemical FOBT screening programme 
were also incorporated.[37] A colonoscopy screening study by Brenner et al was selected due to the 
large sample sizes, broad age range, and the expected similarity between the German and English 
screening populations.[38] To incorporate information on LR adenomas (not reported by Brenner et 
al) and information for persons aged under 60, data from Chung et al 2010 was also included.[39] 
 
The model calibration process applied the Metropolis Hastings (MH) algorithm to generate estimates 
of both CRC natural history model parameters and screening test characteristics from the observed 
data. The aim of model calibration is to obtain parameter sets whose predictions are close to the 
observed data. For a given parameter set, the model can be run to produce predictions of CRC 
incidence, adenoma prevalence and screening outcomes. This Bayesian calibration approach 
produces correlated parameter sets which can be used for probabilistic sensitivity analyses (PSA).[40] 
Correct representation of the joint uncertainty in these parameters is particularly important because of 
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the potential for correlation between several of these parameters. The calibration resulted in a set of 
model parameters which had a good fit to all of the observed data sets used. A comparison of model 
predictions and the observed data sets is presented in the screening reappraisal report.[31,41] 
 
 
4.3. Modelling the effects of an early awareness campaign 
 
 
Effect of an awareness campaign on CRC symptomatic presentation rates 
The effect of an awareness campaign is represented within the model by adjusting the transition 
probabilities from preclinical CRC to clinical CRC to represent the increases in awareness outlined in 
the figure above (Figure 9). The model contains four rates relating to symptomatic or chance 
presentation with Dukes’ A-D CRC. The baseline presentation rates within the model reflect the 
England population from years 2004 to 2006 i.e. before screening commenced. There are two 
potential limitations associated with the modelling of presentation rates. Firstly, the initiation of the 
screening programme may have increased awareness so the presentation rates could have changed 
between 2006 and today. Secondly, the rates of symptomatic presentation vary by Dukes’ stage but 
not by age within the model. This is potentially a limitation; however sufficient data is not available to 
inform an age specific model. 
 
The four transition probabilities are increased to result in an increase in incidence which matches the 
observed increase seen in the pilot campaign. As there were no data available to suggest a change in 
stage distribution as a result of the campaign, we assume that the additional incidence due to the 
awareness campaign is the same as the current CRC stage distribution in England. This is equivalent 
to assuming that the campaign results in the same proportional increase in presentation rates for 
each of the Dukes’ stages. Even if the short-term stage distribution is unchanged by the campaign, 
the additional incidence due to the campaign corresponds to persons presenting earlier than they 
would have in the absence of the campaign. This earlier presentation will result in a change in the 
stage distribution over the following few years. 
The model analysis assumes that the campaign results in a change in the transition probabilities from 
preclinical to clinical CRC and that, subsequently, these probabilities will return to their pre-campaign 
values. The model uses an annual cycle length; however the impact of the campaign is likely to have 
a shorter duration. The method used to adjust annual transition probabilities for a short-term change 
is described in the Appendix 8.7. The annual symptomatic presentation transition probabilities are 
presented in Table 8. 
 
Table 8: Effect of an awareness campaign on CRC symptomatic presentation rates 
 
Dukes A Dukes B Dukes C Stage D
Normal rates in absence of campaign 4.4% 17.6% 36.9% 73.5%
Increased incidence observed 119% 119% 119% 119%
Adjusted rates with campaign
Duration of increase 1 month 4.4% 17.9% 37.4% 74.1%
Duration of increase 3 month 4.6% 18.4% 38.4% 75.5%
Symptomatic presentation rates
 
 
 
Campaign effectiveness by age 
Although the target population for the campaign was persons aged over 55, the nature of the 
campaign meant that persons of all ages were exposed. The GP attendances data suggest that the 
campaign had a smaller effect in the 70+ age group but the magnitude of the effect of age on 
campaign response is unclear. No data were available on the age distribution of the additional GP 
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referrals and CRC diagnoses. As the effect of age on the increase in CRC diagnoses was unknown 
the model assumes that the campaign has the same effect on an individual’s probability of transition 
from preclinical to clinical CRC irrespective of age. 
 
Diagnosis of adenomas and other lower GI conditions 
An awareness campaign may result in an increase in the detection of adenomas. Such an increase 
could change both potential costs and potential benefits as persons with adenomas detected may go 
on to receive surveillance colonoscopy. However, as no data were collected on number of adenomas 
detected as a result of the pilot campaign, this issue was omitted from the modelling. 
 
The awareness campaign is designed to increase presentation rates for symptoms associated with 
CRC. These symptoms are also associated with other lower GI conditions such as Crohns disease, 
ulcerative colitis, inflammatory bowel disease and piles. It is suspected that the campaign may result 
in the earlier diagnosis of some of these other lower GI conditions. However, data on the rates of 
diagnosis of other conditions as a result of the pilot were not collected.  
 
We assume that an earlier diagnosis of any one of these conditions will not be associated with any 
additional costs. Any QALY gain will be of the form: 
 (‘utility with treatment’ – ‘utility without diagnosis & treatment’)*(‘length of time diagnosis is earlier by’) 
However, data on the difference in utility value caused by a diagnosis is not known. Hence, model 
estimates exclude benefits associated with earlier diagnosis of other lower GI conditions so are likely 
to underestimate the true benefit of the campaign. 
 
Duration of effect of campaign 
Data on the duration of the effect of the pilot awareness campaign were very limited. Incidence data 
show an increase for the month of March only but the data are incomplete; see Figure 10. GP 
attendance data show an increase for February-March only, but no data were collected after April 
2011, see section 5. The data on GP referrals suggest that the campaign causes a significant 
increase during the latter half of the campaign and during the 6 weeks following the campaign (i.e. 
April and the start of May), see section 5. The effects of public health campaigns are often short term. 
Without further data the duration of the effect of the campaign is highly uncertain, as illustrated by the 
various possibilities shown in Figure10.  
 
We note a technical point that once the effect of the campaign ends, a slight decrease in attendances 
may be seen due to the slightly lower prevalence of symptoms; this decrease is included within model 
predictions. For the base case analysis we assume that the effects of the campaign on incidence last 
for only one month as illustrated by the available data from the pilot. In the base case we will assume 
that there are no additional GP attendances as a result of the campaign following April 2011. Due to 
the uncertainty surrounding the duration of the effect, a scenario analysis was undertaken in which 
effect was assumed to continue for 3 months. 
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Figure 10:  A representation of the uncertainty in duration of the effect of the campaign on GP  
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Additional versus earlier 
A key issue in evaluating the potential costs and benefits of the awareness campaign is identifying 
whether observed increases in GP attendances/referrals are actually additional or simply earlier. We 
hypothesise that the change in GP attendances as a result of the campaign consists of two 
components:  
(1) An increase due to persons attending earlier, and  
(2) An increase due to persons who would otherwise not have attended their GP (e.g. those 
with transient symptoms not caused by CRC or worried well).  
The proportion of additional GP visits which are additional, rather than simply earlier, are key to 
determining the costs associated with the increased GP attendances linked to the campaign, 
however, no data were available to inform these proportions. As the proportion must lie between 0% 
and 100% the base case analysis assumed 50% of the increase to be additional. To consider this 
uncertainty a scenario analysis applied a proportion of 90%. 
  
Effect of campaign on screening uptake 
The screening data from the pilot regions did not demonstrate a significant increase in uptake 
during/following the awareness campaign period, see section 5. For the purposes of the modelling we 
thus assume that the campaign has no effect on screening uptake.  
 
Efficacy of a repeated campaign 
It is plausible that an effective awareness campaign would be repeated. It is not clear whether a 
repeated campaign may have more effect due to reinforcement of the message or less effective if 
people become familiar with the message and ‘digest’ it less. We note that a repeat of a campaign 
may have slightly less impact on CRC incidence than an initial campaign due to a slightly reduced 
prevalence of symptoms in subsequent years and this effect is represented by the model.  
 
No data were available on the efficacy of a repeated awareness campaign for CRC so evidence from 
other similar campaigns was considered. In the UK, a repeated awareness campaign is in place for 
breast cancer, however, enquires suggested that no data have been collected regarding the efficacy 
of the ‘annual breast cancer awareness month’ in the UK. A US study examined the number of 
diagnoses made in November (one month after national breast cancer awareness month (NBCAM)) 
during years before and after NBCAM was initiated. The study found that during the period when 
breast cancer advocacy was expanding rapidly into a nationwide movement, NBCAM led to an 
increase in the number of November diagnoses. However, during earlier periods when breast cancer 
advocacy was still a grassroots movement, and in later periods when breast cancer advocacy had 
become a well-established nationwide cause, there is little evidence that October NBCAM events had 
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an effect on November diagnoses.[42] None of the studies included in the systematic review included 
repeated campaigns. 
 
Due to the lack of evidence we will assume for the purposes of the cost-effectiveness evaluation that 
the effectiveness remains the same for subsequent campaigns. It is not clear whether this assumption 
overestimates or underestimates the benefit of a repeated campaign.  
 
Model timeframe and comparison 
The campaign is assessed by calculating the costs and benefits accrued for the current population of 
England for the remainder of their lifetimes. To evaluate this we consider a series of 70 cohorts of 
ages 30 to 100 matched to the age distribution of England.[43] For each cohort of age x the model is 
run from the years 30 to x to estimate underlying CRC and adenoma prevalence at age x. At age x 
the awareness campaign (or sequence of campaigns) is applied. Costs incurred and QALYs accrued 
from age x onwards are counted with discounting applied from age x+1 onwards. This process is 
repeated for each of the 70 cohorts to produce population estimates. 
 
Screening in England commenced in 2006 in a few regions with the last regions starting in 2010 (so 
approximately 3 years ago on average). It will be several years until all persons will have been offered 
screening from age 60. We hypothesise that the greater the level of screening a population is 
receiving, the less cost-effective an awareness campaign will be. Hence, an awareness campaign 
may be more cost-effective today than in several years time when all persons have been offered 
screening from age 60. For the purposes of this evaluation the model will assume that screening 
started 3 years ago i.e. persons within the screening age range may have received at most 2 biennial 
screens before the early awareness campaign intervention is applied. 
 
 
Uncertainty analysis 
Several scenario analyses were undertaken to explore the impact of parameter uncertainty:  
- An analysis was undertaken to reflect the potential benefits if the duration of the effect of the 
campaign on incidence was longer than seen in the pilot data.  
- An analysis was undertaken to evaluate the impact of the proportion of GP consultations and 
referrals which were considered to be ‘additional’ rather than ‘earlier’. The base case 
assumed the proportion to be 50% and the scenario analysis applied a proportion of 90%.  
- An analysis was undertaken in which a lower cost of the campaign was applied to reflect the 
lower budgeted cost of the national campaign compared to the pilot campaign. 
 
Due to the significant limitations associated with the pilot campaign data, and the structural 
assumptions which were made, it was felt that PSA would not adequately represent the uncertainty 
present. It was felt that there would be value in undertaking PSA in the future if more complete data 
from the campaign pilot become available. 
 
 
4.4. Costs and utility values used within the model 
A summary of all model parameter values is provided within Appendix 8.7. 
 
Cost of campaign 
In the base case analysis a cost of £0.22 per head of population over the age of 30 was applied which 
corresponds to the cost of the pilot campaign. A scenario analysis was also run in which a lower cost 
of £0.14 was applied to reflect the budgeted cost of the 2012 national campaign.  
 
Cost of additional appointments 
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The awareness campaign may result in additional GP surgery consultations. A GP surgery 
consultation (lasting 11.7 minutes including direct care staff costs and qualification costs, but 
excluding travel costs) has a cost of £36.[44]  
 
The awareness campaign may result in additional appointments in secondary care for suspected 
lower GI cancer. This cost was estimated using a CRC whole disease model which describes 
possible diagnosis pathways.[45]  For persons in whom no cancer is found, the cost of an 
appointment is applied which is estimated to be £544, see Table 9. For persons in whom cancer is 
found, no specific appointment costs is applied as it is assumed that the appointment costs are 
already incorporated within the estimates of cancer treatment cost. 
 
Table 9: Procedures received by persons referred for suspected lower GI cancer (in whom CRC is not 
found)  
 
Procedure Probability Cost
Receive CT pneumocolon / CT as unfit for endoscopy 0.015            157.35£         
Receive colonoscopy as first test 0.936            563.45£         
Receive a repeat test after first COL (probably barium enema) 0.075            117.43£         
Receive barium enema first due to presence of mass (can't have COL) 0.049            117.43£         
Total average cost per person 544.18£         
* Costs taken from NHS reference costs 2011, probabilities taken from Tappenden 2011  
 
 
Cost of CRC treatment 
The awareness campaign may result in a change in the stage distribution of diagnosed CRC thus 
effecting total CRC treatment costs. The cost of CRC treatment according to Dukes’ stage at 
diagnosis were estimated specifically for this project using a CRC whole disease model.[45] The costs 
generated are lower than those used in previous work as they reflect patient pathways more 
accurately and incorporate more recent unit costs. Costs which are dependent on age were used to 
reflect variations in treatment rates; see Table 10 and Figure 11.  
 
Table10: Average colorectal cancer treatment cost by Dukes' stage at diagnosis 
 
A B C D
40-49 8,375£    8,362£    13,862£   11,198£   
50-59 5,465£    6,712£    9,272£     8,078£     
60-69 4,423£    5,120£    6,945£     6,227£     
70-79 3,040£    3,305£    4,291£     4,176£     
80-100 1,320£    1,479£    1,493£     772£       
Age at 
diagnosis
Dukes' Stage at diagnosis
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Figure 11: Average colorectal cancer treatment cost by Dukes' stage at diagnosis 
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Other costs included within the model 
As the awareness campaign may impact on the both the number of persons attending screening and 
the number of CRC cases diagnosed via screening, the costs associated with CRC screening were 
incorporated. These costs are detailed in the report “Reappraisal of the options for CRC 
screening”.[31] Several costs were updated within the model using 2011 Reference Costs. The new 
costs used are detailed in Appendix 8.7.  
 
Utility values 
General utility values for a person with and without cancer were applied as there were issues and 
inconsistencies with CRC-specific utility data. Full details of the other values identified and the 
inconsistencies identified are provided in the report “Reappraisal of the options for CRC 
screening”.[31] Persons with cancer were assigned a utility value of 0.697 and persons without cancer 
a value of 0.798 taken from the health survey for England.[46] Utility values were assumed to be the 
same regardless of Dukes’ stage and age.  
 
5. Cost-Effectiveness Results 
 
This chapter presents lifetime results which reflect the entire population of England. A breakdown of 
total costs is presented and includes: campaign costs, CRC treatment costs, costs associated with 
additional GP attendances and referrals. In addition to total QALYs changes in cancer incidence, 
cancer stage distribution, and cancer mortality are presented. 
 
Base case results 
Table 11 presents model predictions for no awareness campaign, a one-off awareness campaign and 
an annual awareness campaign for five years. The change compared to ‘no campaign’ is presented. 
The results reflect model predictions for effects on incidence for the lifetime of the entire current 
population of England aged over 30. Hence the total incidence figures are very high as they include 
cases of CRC presenting for up to 70 years (in the case of a 30-year-old living to age 100). 
 
Even though the effect of the campaign on the rates of symptomatic presentation are assumed the 
same for each Dukes’ stage, the additional incidence due to the campaign corresponds to persons 
presenting earlier than they would have in the absence of the campaign. This earlier presentation 
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results in a change in the stage distribution over the following few years which in turn has a direct 
impact on CRC mortality. 
 
In our base case model the campaign causes an increase in the number of cases of Dukes’ stage A-
C presenting symptomatically and a decrease in the number of cases of stage D(e.g. 92 less cases of 
Stage D CRC occur as a result of the campaign). Overall, there is an increase in the number of cases 
of CRC presenting symptomatically. A small decrease is seen in the number of screen/surveillance 
detected cases because of the increase in cases presenting symptomatically. Overall there is an 
increase in CRC incidence and this corresponds to a decrease in the number of persons dying with 
undiagnosed CRC. A significant reduction in CRC specific deaths was seen which was due to the 
reduction in the number of cases of CRC presenting in stage D. This reduction in deaths 
corresponded to an increase in QALYs gained. 
 
The results show a reduction in total costs associated with screening caused by a decrease in the 
number of positives at screening since more CRC presents symptomatically. An increase in CRC 
treatment costs is seen for two reasons. Firstly, CRC is presenting at younger ages which are 
associated with higher treatment costs. Secondly, there is a shift of cases from stage D to Dukes’ C, 
and Dukes’ C CRC is associated with higher treatment costs than Stage D. Costs associated with 
increased GP consultations and referrals account for only a small proportion of total costs and are 
considerably less than the cost of the campaign itself.  
 
The total (discounted) cost associated with the one-off campaign was approximately £5.5 million. 
Assuming an increase in symptomatic presentation rates of 10% for a period of 1 month, the 
campaign prevented 66 deaths from CRC resulting in a gain of 404 QALYs. The ICER for the one-off 
awareness campaign was £13,496 per QALY gained, compared to ‘no campaign’ giving a NMB of 
£2.6 million. The total (discounted) cost associated with the campaign repeated annually for 5 years 
was approximately £25 million. The campaign prevented 330 deaths from CRC resulting in a gain of 
1,898 QALYs. The ICER for the 5-year awareness campaign was £13,032 per QALY compared to ‘no 
campaign’ giving a NMB of £13 million. 
 
A sensitivity analysis demonstrated that the ICER associated with a one-off awareness campaign 
would be less than £20,000 per QALY (the threshold commonly used by NICE) if  an increase in 
symptomatic presentation rates of at least 7% was obtained for a period of 1 month. 
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Table 11a: Model predictions for a one-off awareness campaign and five years of annual awareness campaigns (total and percentage change compared to 
‘no campaign’) 
No awareness 
campaign
One-off 
awareness 
campaign
Five years of 
annual 
awareness 
One-off 
awareness 
campaign
Five years of 
annual 
awareness 
Dukes' A CRC, symptomatic presentation 169,904            169,930            170,037            26 133
Dukes' B CRC, symptomatic presentation 413,428            413,480            413,691            52 262
Dukes' C CRC, symptomatic presentation 562,025            562,059            562,193            33 167
Dukes' D CRC, symptomatic presentation 635,013            634,921            634,551            -92 -462 
Total incidence through symptomatic presentation 1,780,370         1,780,390         1,780,472         20 101
Dukes' A CRC, screen/surveillance detected 67,653             67,653             67,651             -0 -2 
Dukes' B CRC, screen/surveillance detected 37,818             37,817             37,813             -1 -5 
Dukes'  C CRC, screen/surveillance detected 22,595             22,593             22,585             -2 -10 
Dukes' D CRC, screen/surveillance detected 9,875               9,873               9,865               -2 -10 
Total incidence though screening/surveillance 137,940            137,935            137,914            -5 -27 
CRC-specific deaths 1,020,002         1,019,937         1,019,673         -66 -330 
Deaths with undiagnosed CRC 535,114            535,100            535,041            -14 -73 
Total costs related to screening (discounted) 991,214,492     991,211,085     991,198,885     3,407-£             15,607-£            
Cancer management (inc. pathology) costs (discounted) 3,613,360,394   3,613,454,837   3,613,807,545   94,443£            447,151£          
Cost of additional GP consultations/referrals (discounted) -                   855,716            3,882,488         855,716£          3,882,488£       
Cost of awareness campaign (discounted) -£                 4,499,995£       20,417,036       4,499,995£       20,417,036£     
Total cost (discounted) 4,604,574,886£ 4,610,021,632£ 4,629,305,955   5,446,745£       24,731,068£     
Total life years gained (discounted) 559,242,232     559,242,854     559,245,158     622                  2,926               
Total QALYs gained (discounted) 445,074,314     445,074,718     445,076,212     404                  1,898               
Change compared to 'no 
awareness campaign'
Model predictions for the current population of 
England evaluated over a lifetime
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 Table 11b: Model predictions for a one-off awareness campaign and five years of annual awareness campaigns (percentage change compared to ‘no 
campaign’) 
Change compared to "No awareness campaign" for 
the population of England
Dukes' A CRC, symptomatic presentation 26 0.0% 133 0.1%
Dukes' B CRC, symptomatic presentation 52 0.0% 262 0.1%
Dukes' C CRC, symptomatic presentation 33 0.0% 167 0.0%
Dukes' D CRC, symptomatic presentation -92 0.0% -462 -0.1%
Total incidence through symptomatic presentation 20 101
Dukes' A CRC, screen/surveillance detected -0 0.0% -2 0.0%
Dukes' B CRC, screen/surveillance detected -1 0.0% -5 0.0%
Dukes'  C CRC, screen/surveillance detected -2 0.0% -10 0.0%
Dukes' D CRC, screen/surveillance detected -2 0.0% -10 -0.1%
Total incidence though screening/surveillance -5 -27 
CRC-specific deaths -66 0.0% -330 0.0%
Deaths with undiagnosed CRC -14 0.0% -73 0.0%
Total costs related to screening (discounted) 3,407-£         0.0% 15,607-£          0.0%
Cancer management (inc. pathology) costs (discounted) 94,443£       0.0% 447,151£         0.0%
Cost of additional GP consultations/referrals (discounted) 855,716£      0.0% 3,882,488£      0.0%
Cost of awareness campaign (discounted) 4,499,995£   0.0% 20,417,036£    0.0%
Total cost (discounted) 5,446,745£   0.1% 24,731,068£    0.5%
Total life years gained (discounted) 622              0.0% 2,926              0.0%
Total QALYs gained (discounted) 404              0.0% 1,898              0.0%
ICER 13,496£       13,032£          
NMB 2,624,770£   13,222,909£    
One-off awareness 
campaign
Five years of annual 
awareness campaign
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Scenario analyses 
Several scenario analyses were undertaken to test the impact of model assumptions and data 
uncertainty on the results. These analyses are presented in Tables 12 and 13. 
 
(1) Duration of effect of campaign on incidence 
The base case assumed an increase in symptomatic presentation rates of 10% for one month. A 
scenario analysis which assumed the effect of the campaign on presentation rates and incidence 
continued for 3 months was performed. In this scenario the number of additional GP attendances and 
referrals was not changed from the base case. This scenario analysis resulted in 202 less CRC 
deaths compared to ‘no campaign’. This led to a gain of 1,243 QALYs and an ICER of £4,536 per 
QALY gained. 
 
(2) Proportion of increased attendances which are assumed to be additional 
The base case assumed that 50% of the increased GP consultation and referrals associated with the 
campaign were additional rather than earlier but this value is highly uncertain. A scenario analysis 
considered a proportion of 90%. Although there will be a relationship between this proportion and the 
impact of the campaign on incidence, this relationship is unknown. So, for this sensitivity analysis the 
impact of the campaign on CRC incidence was not changed. This analysis resulted in a total cost of 
additional GP attendances and consultations of approximately £1.5 million which increased the ICER 
to £15,192 per QALY gained. Hence the cost-effectiveness results are not very sensitive to this highly 
uncertain parameter. 
 
(3) Duration, magnitude and stage distribution of the increase in incidence immediately following 
the campaign 
The sensitivity analysis demonstrates that the ICER associated with an awareness campaign is highly 
dependent on the magnitude of the increase in incidence following the campaign, the duration of the 
increase in incidence following the campaign and the stage distribution of any additional incidence 
following the campaign. For example, if the magnitude of the increase was just 5% and restricted to 
Dukes’ C and stage D CRC then the ICER is approximately £55,000 per QALY. 
 
Table 12: Scenario analyses to explore the effect of varying uncertain parameters Model predictions 
for a one-off awareness campaign (total change compared to ‘no campaign’ and % change) 
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Change compared to "No awareness campaign" for 
the population of England
Dukes' A CRC, symptomatic presentation 26 0.0% 80 0.0% 26 0.0%
Dukes' B CRC, symptomatic presentation 52 0.0% 159 0.0% 52 0.0%
Dukes' C CRC, symptomatic presentation 33 0.0% 107 0.0% 33 0.0%
Dukes' D CRC, symptomatic presentation -92 0.0% -283 0.0% -92 0.0%
Total incidence through symptomatic presentation 20 62 20
Dukes' A CRC, screen/surveillance detected -0 0.0% -1 0.0% -0 0.0%
Dukes' B CRC, screen/surveillance detected -1 0.0% -3 0.0% -1 0.0%
Dukes'  C CRC, screen/surveillance detected -2 0.0% -6 0.0% -2 0.0%
Dukes' D CRC, screen/surveillance detected -2 0.0% -7 -0.1% -2 0.0%
Total incidence though screening/surveillance -5 -17 -5 
CRC-specific deaths -66 0.0% -202 0.0% -66 0.0%
Deaths with undiagnosed CRC -14 0.0% -44 0.0% -14 0.0%
Total costs related to screening (discounted) 3,407-£         0.0% 10,482-£          0.0% 3,407-£       0.0%
Cancer management (inc. pathology) costs (discounted) 94,443£       0.0% 295,434£         0.0% 94,443£     0.0%
Cost of additional GP consultations/referrals (discounted) 855,716£      0.0% 855,716£         0.0% 1,540,288£ 0.0%
Cost of awareness campaign (discounted) 4,499,995£   0.0% 4,499,995£      0.0% 4,499,995£ 0.0%
Total cost (discounted) 5,446,745£   0.1% 5,640,663£      0.1% 6,131,318£ 0.1%
Total life years gained (discounted) 622              0.0% 1,917              0.0% 622            0.0%
Total QALYs gained (discounted) 404              0.0% 1,243              0.0% 404            0.0%
ICER 13,496£       4,536£            15,192£     
NMB 2,624,770£   19,229,261£    1,940,197£ 
90% of GP referrals/ 
consultations increase 
is additional
One-off awareness campaign
Effect duration = 3 months
Base case: Effect 
duration = 1 month, 50% 
of GP referrals/ 
consultations increase is 
additional
 
 
Table 13: Sensitivity analysis on duration, magnitude and stage distribution of the increase in 
incidence immediately following the campaign 
Duration of increase Magnitude of increase
Identical increase in Dukes' stages A-D
1 month 5% 26,767£       25,818£       
1 month 10% 13,496£       13,032£       
3 months 5% 8,843£         8,549£         
Increase in Dukes' C and Stage D only
1 month 5% 55,210£       53,272£       
1 month 10% 27,826£       26,868£       
1 month 20% 14,135£       13,666£       
3 months 5% 17,965£       17,359£       
ICERIncrease in CRC incidence immediatley following the 
awareness campaign One-off 
awareness 
campaign
Five years of 
annual 
awareness 
 
 
Comparison with a campaign to improve screening uptake 
In the model base case 37% of people never attend screening and 85% of the remainder population 
attend in each round giving an overall uptake by round of 54% as seen in NHS BCSP. An exploratory 
analysis was undertaken to allow a comparison between the potential benefits associated with an 
awareness campaign compared with the potential benefits associated with an intervention designed 
to increase screening uptake. The exploratory analysis considered the potential benefits associated 
with a reduction in the number of persons never attending screening by 1% and 10%1. A reduction in 
screening non-attendees of 10% has the potential to reduce CRC mortality by considerably more than 
may be achieved by a one-off awareness campaign. 
1 Note: this analysis assumes that if a person is removed from the screening non-attendees group 
they will continue to attend screening rounds with a probability of 85% 
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Table 14: Comparison of awareness campaign with an intervention which increases screening uptake 
Change compared to "No awareness campaign" for 
the population of England
Dukes' A CRC, symptomatic presentation 26 0.0% -5 0.0% -50 0.0%
Dukes' B CRC, symptomatic presentation 52 0.0% -16 0.0% -153 0.0%
Dukes' C CRC, symptomatic presentation 33 0.0% -27 0.0% -255 0.0%
Dukes' D CRC, symptomatic presentation -92 0.0% -36 0.0% -341 -0.1%
Total incidence through symptomatic presentation 20 -83 -798 
Dukes' A CRC, screen/surveillance detected -0 0.0% 18 0.0% 175 0.3%
Dukes' B CRC, screen/surveillance detected -1 0.0% 13 0.0% 125 0.3%
Dukes'  C CRC, screen/surveillance detected -2 0.0% 10 0.0% 94 0.4%
Dukes' D CRC, screen/surveillance detected -2 0.0% 5 0.0% 46 0.5%
Total incidence though screening/surveillance -5 46 440
CRC-specific deaths -66 0.0% -38 0.0% -359 0.0%
Deaths with undiagnosed CRC -14 0.0% -14 0.0% -136 0.0%
One-off awareness 
campaign
Reduction in number of 
persons never attending 
screening by 1%
Reduction in number of 
persons never attending 
screening by 10%
 
 
 
 
6. Conclusions 
 
The clinical evidence review yielded eleven studies which met the inclusion and exclusion criteria. 
Only one study was an RCT. The mapping review reported the characteristics of an additional 56 
interventions, though this review has limitations. Of the eleven included studies, most studies were 
from the USA and mainly focussed on BME or socio-economically disadvantaged subgroups within 
the general population. Only four studies involved interventions which aimed to increase early 
presentation on the basis of symptoms whilst the remainder aimed to increase screening attendance. 
Data on campaigns in the UK were under-reported and often unpublished. Overall, studies were not 
reported well enough to enable an assessment of risk of bias, but seemed likely to be of moderate to 
high risk of bias. As such, all results should be interpreted with caution.  
 
Studies tended to report positive results at all stages of the logic model, but it is not possible to draw 
comparative conclusions between interventions, or which components of interventions, conferred the 
positive effects. The logic model was generally supported, though evidence to inform the link between 
increased self-presentations to a GP or increased screening attendance leading to increased early 
detection and decreased morbidity and mortality was lacking. Only one study reported data for 
increased early detection, and found a non-significant increase in detection of CRC with no spread. It 
is unclear whether a larger event rate/sample size, or a more sensitive measure of progression also 
including pre-cancerous states, may have produced a significant result. It is also unclear what 
constitutes a clinically relevant change in early detection. The final stage in the logic model, mortality 
and morbidity, may have been more sensitive to the effects of earlier detection but would require 
much longer study durations.  
 
A cost-effectiveness analysis was undertaken based on data from the pilot signs and symptoms 
campaign. The reliance on this single study is a major limitation. There were several key limitations 
associated with data available from the pilot signs and symptoms campaign: 
• Although an increase in CRC incidence was observed in March 2011 compared to the 
previous year, there is considerable uncertainty surrounding whether this increase was in fact 
due to the pilot campaign. Monthly variations may occur as a result of factors such as: 
different length months, different numbers of clinics, different numbers of working days, etc. 
An analysis of similar incidence data non-pilot regions was not available. 
• Data on GP consultation numbers was not collected for a long enough period to see the 
duration of the effect of the campaign on GP consultations.  
• The increase in GP referrals seen in the Cancer Wait times was only available for one of the 
pilot regions and was not available for a long enough period to see the duration of the effect 
of the campaign on GP referrals. 
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• The data on the stage distribution of CRC following the pilot involved very small numbers so it 
was not possible to draw any significant conclusions. 
• No data on the effect of the campaign on GP referrals or CRC incidence by age was 
available.  
• There was no information on what proportion of the increase in GP consultations and GP 
referrals are likely to be ‘additional’ as opposed to ‘earlier’. 
• There was no information on the increase in the detection of adenomas or the increase in the 
detection of other lower GI conditions which have similar symptoms to CRC. 
• No data was available on the effect of the campaign on rates of emergency presentation with 
CRC. A reduction in emergency presentation rates could potentially lead to cost savings. 
 
Due to limitations with the data available it was necessary to make several assumptions: 
• The duration of the effect of the campaign was assumed to be short-lived with an increase in 
CRC incidence only observed for one month following the campaign. 
• The campaign was assumed to have the same proportional effect on presentation rates for 
each CRC stage. 
• The campaign was assumed to have the same effect on presentation rates for all age groups. 
• Of the increases in GP consultations and GP referrals, it was assumed that 50% were 
‘additional’ (i.e. would not have otherwise occurred) as opposed to ‘earlier’ (i.e. would have 
occurred at a later date). 
 
Given these assumptions, the analysis demonstrated that an awareness campaign would be cost- 
effective with an ICER of £13,496 per QALY gained. Assuming that a repeated annual campaign 
would have similar effects, a 5-year repeated campaign would have a similar ICER. Scenario 
analyses showed that the ICER would increase slightly if a higher proportion of the increase in GP 
consultations/referrals were additional as opposed to earlier. The results of the analysis are highly 
sensitive to changes in the duration of the effect of the campaign. If the duration of the effects were 
assumed to last for 3 months rather than 1 month, QALY gains would increase considerably and the 
ICER would reduce to approximately £4,500 per QALY gained. If the campaign only affects 
symptomatic presentation rates for late stage CRC then the ICER may increase to £28K. An 
exploratory analysis which compared the benefits of an awareness campaign (that increased 
symptomatic presentation rates by 10% for 1 month) to a screening campaign (that reduced the 
number of persons never attending screening by 10%) demonstrated that the screening campaign 
would reduce five times the number of CRC deaths compared to the awareness campaign. 
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 7. Priorities for Future Research 
 
Design of early awareness interventions  
The studies described within the systematic review highlight the range of early awareness 
interventions which are potentially effective. Such interventions should be considered when designing 
a future campaign or targeted intervention, and the lessons of previous campaigns taken into account.   
 
Several interventions made use of focus groups in the design stage, and two interventions involved 
the target community in the design and delivery of the intervention. It is unclear whether such 
approaches confer an effective advantage, and future research may focus on ascertaining whether 
this is the case. 
 
An intervention can be designed to target specific subgroups such as a particular socioeconomic 
group, age group or region. As areas of socioeconomic deprivation are known to be associated with 
lower levels of screening uptake and slightly higher levels of CRC, [47] campaigns focussing on the 
different needs of such groups are likely to have different cost-effectiveness due to different resource 
implications and different QALY gains to be made. This is especially true where community 
engagement and tailoring to the socio-cultural norms of an area is involved. This general principle 
also holds true for all campaigns, and it is likely that an evaluation, ideally at multiple heterogeneous 
sites, of any new campaign is necessary to ascertain its effectiveness and cost-effectiveness.  
 
Campaign monitoring and data collection 
During the process of this review, a number of CRC campaigns that have been trialled or 
implemented regionally across the UK were encountered, but, as they were not evaluated, they were 
not includable in the review and their efficacy and cost-effectiveness remains unknown. One UK 
study’s (Lyons et al)[13] umbrella organisation (Improvement Foundation) dissolved before the project 
evaluation was completed. Another (WoSCAP)[12] is only available through the Cancer Research UK 
website as an unpublished report to funders; the project website itself, which is referred to as a source 
of additional material, appears to no longer be available (presumably due to the end of funding). The 
third (Ramsay)[14] is (as yet) unpublished and only available as an online report. The data available 
from the ‘signs and symptoms’ pilot campaign which was used in the cost-effectiveness modelling 
was associated with serious limitations which have been discussed previously. It would therefore 
seem that a priority for future research is to co-ordinate and maximise the evaluation and 
dissemination of efforts that are already been made to increase CRC awareness in a way that is not 
dependent on short-term project funding.   
 
Few studies encountered throughout this review reported the number of diagnoses achieved as a 
result of the intervention, and none reported the final outcome: mortality. Data relating to the link 
between increased self-presentation or increased screening and increased early detection should be 
sought, either through primary or secondary research. Ideally, all studies assessing the effectiveness 
of CRC interventions should include ‘stage at’ diagnosis and number of diagnoses.  
 
Few studies were at low risk of bias. Future research should consider carefully the sources of bias 
and confounding that non-randomised studies are prone to and seek to minimise their potential to 
influence the study. As event rates are low, any future studies should carefully consider the power of 
the sample size to detect small but clinically relevant changes in outcomes.  
 
Specific suggestions for improved monitoring of campaigns include: 
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• To allow a clear observation of the duration of the effect of a campaign it is suggested that 
data be collected for a period of at least two years (one year before campaign and one year 
after campaign). This approach would also allow observation of seasonal variations so these 
could be differentiated from the effect of the campaign. 
• Comparison with other non-intervention regions to establish whether any changes observed 
are likely to be attributable to the campaign. 
• Investigation of reasons behind regional variations in campaign effect. 
• To enable information to be obtained on the effect of the campaign on different age groups: 
all should be reported and split into 5- or 10-year age bands.  
• An analysis of the effects of an awareness campaign should incorporate data on GP 
consultations, GP referrals, and CRC incidence (by stage) if possible. 
• If possible, data on the rates of diagnosis of other lower GI conditions which have similar 
symptoms to CRC should be collected. 
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 8. Appendix 
8.1. Appendix: Search strategy 
 
Database/sources searched 
 
1. Medline and Medline in Process & Other Non-Indexed citations (Ovid)     
2. Embase (Ovid)   
3. Cochrane Database of Systematic Reviews (Cochrane)   
4. Cochrane Central Register of Controlled Trials (Cochrane)  
5. NHS Health Economic Evaluation Database (Cochrane)      
6. Health Technology Assessment Database (Cochrane)   
7. Database of Abstracts of Review of Effects (Cochrane)  
8. Science Citation Index (Web of Science)   
9. Social Science Citation Index (Web of Science) 
10. Conference Proceedings index (Web of Science) 
11. Cumulative Index to Nursing and Allied Health Literature (EBSCO) 
12. PsycINFO (Ovid)  
13. Health Management Information Consortium (Ovid) 
14. Social Policy and Practice (Ovid) 
15. Dissertation Abstracts (ProQuest) 
16. UK CRN Portfolio Database (NIHR)  
17. Clinical Trials.gov (NIH) 
18. Open Grey 
19. American Society of Cancer Oncology 
20. European Society for Medical Oncology 
21. Cancer registers (see separate document) 
 
Limits applied 
 
Date: None 
Language: English only 
Study design: None 
Country of publication: None 
 
Summary table of searches 
 
Database Keywords in 
database 
Records 
retrieved 
With bowel Total 
Medline and Medline in Process & 
Other Non-Indexed citations  
$$medline 557 +9 566 
EMBASE $$embase 681 +22 703 
Cochrane Library $$cochrane 143 +2 145 
SCI-E, SSCI, CPI-S  $$wos 754 +95 849 
CINAHL $$cinahl 215 +3 218 
PsycINFO  $$psycinfo 62 +2 64 
HMIC $$hmic 29 +16 45 
Social Policy and Practice $$spp 24 +9 33 
Dissertation Abstracts $$proquest 193 +3 196 
Total retrieved - 2658 161 2819 
51 
 
Number of unique records in 
database 
$$electronic 
searches 
1804 131 - 
UK CRN See end 6 - - 
Clinical Trials.gov See end 16 -  
metaRegister of Controlled Trials See end 1 -  
Open Grey See end 17 -  
ASCO See end 20 -  
ESMO See end 25 -  
Cancer registers NA Selective -  
Records in Word file - 85 -  
 
 
 
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R): Ovid. 1948 to Present 
1st December 2011 
 
1. exp Colorectal Neoplasms/ 
2. exp Cecal Neoplasms/ 
3. ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
4. ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ 
or adenocarcinoma$)).ti,ab. 
5. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
6. ((sigmoid$ or rectosigmoi$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
7. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or 
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$)).ti,ab. 
8. (bowel$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
9. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
10. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
11. (hepatic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
12. (splenic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
13. or/1-12 
14. exp Health Promotion/ 
15. health promotion.tw. 
16. promot$ health.tw. 
17. Health Education/ 
18. health education.tw. 
19. Patient Education as topic/ 
20. Mass Media/ 
21. Social Marketing/ 
22. social marketing.tw. 
23. campaign$.tw. 
24. or/14-23 
25. Awareness/ 
26. (aware$ or knowledge$ or attitude$ or recogni$).tw. 
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27. 25 or 26 
28. (delay$ or late or later or early or earlier or postpone$ or wait$ or accept$ or deny or denial or 
promot$).tw. 
29. (helpseeking or diagnos$ or present$ or detect$ or attend$ or consult$ or seek or sought or refer 
or treatment or care).tw. 
30. 28 and 29 
31. (symptom$ and (detect$ or identif$)).tw. 
32. 30 or 31 
33. 13 and 24 and 27 
34. 13 and 24 and 32 
35. 33 or 34 
36. limit 35 to English language 
 
Embase: Ovid. 1974 to 2011 Week 47 
December 2011 
 
1. exp large intestine tumor/ 
2. ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
3. ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ 
or adenocarcinoma$)).ti,ab. 
4. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
5. ((sigmoid$ or rectosigmoi$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
6. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or 
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$)).ti,ab. 
7. (bowel$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
8. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
9. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
10. (hepatic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
11. (splenic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
12. or/1-11 
13. exp health promotion/ 
14. health promotion.tw. 
15. promot$ health.tw. 
16. health education/ 
17. health education.tw. 
18. patient education/ 
19. mass medium/ 
20. social marketing/ 
21. social marketing.tw. 
22. campaign$.tw. 
23. or/13-22 
24. awareness/ 
25. (aware$ or knowledge$ or attitude$ or recogni$).tw. 
26. 24 or 25 
53 
 
27. (delay$ or late or later or early or earlier or postpone$ or wait$ or accept$ or deny or denial or 
promot$).tw. 
28. (helpseeking or diagnos$ or present$ or detect$ or attend$ or consult$ or seek or sought or refer 
or treatment or care).tw. 
29. 27 and 28 
30. (symptom$ and (detect$ or identif$)).tw. 
31. 29 or 30 
32. 12 and 23 and 26 
33. 12 and 23 and 31 
34. 32 or 33 
35. limit 34 to English language 
 
Cochrane Database of Systematic Reviews (CDR): Wiley Interscience. 1996-present 
Cochrane Central Register of Controlled Trials (CCRT): Wiley Interscience. 1898-present 
NHS Economic Evaluation Database (NHS EED): Wiley Interscience. 1995-present 
Health Technology Assessment Database (HTA): Wiley Interscience. 1995-present 
Database of Abstracts of Reviews of Effects (DARE)): Wiley Interscience. 1995-present 
1st December 2011 
 
#1 MeSH descriptor Colorectal Neoplasms explode all trees 
#2 MeSH descriptor Cecal Neoplasms explode all trees 
#3 ((colorect* near cancer*) or (colorect* near neoplasm*) or (colorect* near malignan*) or 
(colorect* near oncolog*) or (colorect* near tumor*) or (colorect* near tumour*) or (colorect* 
near carcinoma*) or (colorect* near adenocarcinoma*)) 
#4 ((colon* near cancer*) or (colon* near neoplasm*) or (colon* near malignan*) or (colon* near 
oncolog*) or (colon* near tumor*) or (colon* near tumour*) or (colon* near carcinoma*) or 
(colon* near adenocarcinoma*)) 
#5 ((rectal* near cancer*) or (rectal* near neoplasm*) or (rectal* near malignan*) or (rectal* near 
oncolog*) or (rectal* near tumor*) or (rectal* near tumour*) or (rectal* near carcinoma*) or 
(rectal* near adenocarcinoma*)) 
#6 ((rectum* near cancer*) or (rectum* near neoplasm*) or (rectum* near malignan*) or (rectum* 
near oncolog*) or (rectum* near tumor*) or (rectum* near tumour*) or (rectum* near 
carcinoma*) or (rectum* near adenocarcinoma*)) 
#7 ((sigmoid* near cancer*) or (sigmoid* near neoplasm*) or (sigmoid* near malignan*) or 
(sigmoid* near oncolog*) or (sigmoid* near tumor*) or (sigmoid* near tumour*) or (sigmoid* 
near carcinoma*) or (sigmoid* near adenocarcinoma*)) 
#8 ((cecum* near cancer*) or (cecum* near neoplasm*) or (cecum* near malignan*) or (cecum* 
near oncolog*) or (cecum* near tumor*) or (cecum* near tumour*) or (cecum* near 
carcinoma*) or (cecum* near adenocarcinoma*)) 
#9 ((cecal* near cancer*) or (cecal* near neoplasm*) or (cecal* near malignan*) or (cecal* near 
oncolog*) or (cecal* near tumor*) or (cecal* near tumour*) or (cecal* near carcinoma*) or 
(cecal* near adenocarcinoma*)) 
#10 ((bowel* near cancer*) or (bowel* near neoplasm*) or (bowel* near malignan*) or 
(bowel* near oncolog*) or (bowel* near tumor*) or (bowel* near tumour*) or (bowel* 
near carcinoma*) or (bowel* near adenocarcinoma*)) 
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 or #10) 
#12 MeSH descriptor Health Promotion explode all trees 
#13 (health promotion):ti,ab,kw 
#14 (promot* health):ti,ab,kw 
#15 MeSH descriptor Health Education explode all trees 
#16 (health education):ti,ab,kw 
#17 MeSH descriptor Patient Education as Topic, this term only 
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#18 MeSH descriptor Mass Media, this term only 
#19 MeSH descriptor Social Marketing, this term only 
#20 (social marketing):ti,ab,kw 
#21 (campaign*):ti,ab,kw 
#22 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21) 
#23 MeSH descriptor Awareness, this term only 
#24 (aware* or knowledge* or attitude* or recogni*):ti,ab,kw 
#25 (#23 OR #24) 
#26 (delay* or late or later or early or earlier or postpone* or wait* or accept* or deny or denial or 
promot*):ti,ab,kw 
#27 (helpseeking or diagnos* or present* or detect* or attend* or consult* or seek or sought or 
refer or treatment or care):ti,ab,kw 
#28 (#26 AND #27) 
#29 (symptom* and (detect* or identif*)):ti,ab,kw 
#30 (#28 OR #29) 
#31 (#11 AND #22 AND #25) 
#32 (#11 AND #22 AND #30) 
#33 (#31 OR #32) 
 
Science Citation Index (SCI): Web of Science 1899-present 
Social Science Citation Index (SSCI): Web of Science 1956-present 
Conference Proceedings Index (CPI): Web of Science 1990-present 
1st December 2011 
 
# 11 #9 AND #6 AND #5  
Refined by: Languages=( ENGLISH )  
# 10 #9 AND #6 AND #5  
# 9 #7 OR #8   
# 8 Topic=(((delay* or late or later or early or earlier or postpone* or wait* or accept* or deny or 
denial or promot*) NEAR/20 (helpseeking or diagnos* or present* or detect* or attend* or 
consult* or seek or sought or refer or treatment or care)))  
# 7 Topic=(aware* or knowledge* or attitude* or recogni*)  
# 6 Topic=((“health promotion”) or (“promot* health”) or (“health education”) or (“patient 
education”) or media or (“social marketing”) or campaign*)  
# 5 #4 OR #3 OR #2 OR #1  
# 4 Topic=(bowel* cancer* or bowel* neoplasm* or bowel* tumo*r* or bowel* 
adenocarcinoma or bowel* carcinoma) 
# 3 Topic=(colon* cancer* or colon* neoplasm* or colon* tumo*r* or colon* adenocarcinoma or 
colon* carcinoma)  
# 2 Topic=(rectal cancer* or rectal neoplasm* or rectal tumo*r* or rectal adenocarcinoma or rectal 
carcinoma)  
# 1 Topic=(colorectal cancer* or colorectal neoplasm* or colorectal tumo*r* or colorectal  
adenocarcinoma or colorectal carcinoma)  
 
CINAHL: EBSCO.  
1st December 2011 
 
S33 S17 and S28 and S31 Limiters - English Language  
S32 S17 and S28 and S31  
S31  S29 or S30  
S30 TI ( (((delay* or late or later or early or earlier or postpone* or wait* or accept* or deny or 
denial or promot*) N20 (helpseeking or diagnos* or present* or detect* or attend* or consult* 
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or seek or sought or refer or treatment or care))) ) OR AB ( (((delay* or late or later or early or 
earlier or postpone* or wait* or accept* or deny or denial or promot*) N20 (helpseeking or 
diagnos* or present* or detect* or attend* or consult* or seek or sought or refer or treatment 
or care))) )  
S29  TI ( aware* or knowledge* or attitude* or recogni* ) OR AB ( aware* or knowledge* or attitude* 
or recogni* )  
S28  S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27  
S27 TI campaign* OR AB campaign*  
S26 TI social marketing OR AB social marketing  
S25 (MH "Social Marketing")  
S24 (MH "Telecommunications+")  
S23 TI patient education OR AB patient education  
S22 TI health education OR AB health education  
S21 (MH "Health Education+")  
S20 TI promot* health OR AB promot* health  
S19 TI health promotion OR AB health promotion  
S18 (MH "Health Promotion+")  
S17 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or 
S15 or S16  
S16 TI ( splenic flexur* cancer* or splenic flexur* neoplasm* or splenic flexur* tumo*r* or splenic 
flexur* adenocarcinoma or splenic flexur* carcinoma ) OR AB ( splenic flexur* cancer* or 
splenic flexur* neoplasm* or splenic flexur* tumo*r* or splenic flexur* adenocarcinoma or 
splenic flexur* carcinoma )  
S15 TI ( hepatic flexur* cancer* or hepatic flexur* neoplasm* or hepatic flexur* tumo*r* or hepatic 
flexur* adenocarcinoma or hepatic flexur* carcinoma ) OR AB ( hepatic flexur* cancer* or 
hepatic flexur* neoplasm* or hepatic flexur* tumo*r* or hepatic flexur* adenocarcinoma or 
hepatic flexur* carcinoma )  
S14 TI ( (large intestin* cancer* or large intestin* neoplasm* or large intestin* tumo*r* or large 
intestin* adenocarcinoma or large intestin* carcinoma) ) OR AB ( (large intestin* cancer* or 
large intestin* neoplasm* or large intestin* tumo*r* or large intestin* adenocarcinoma or large 
intestin* carcinoma) )  
S13 TI ( (bowel* cancer* or bowel* neoplasm* or bowel* tumo*r* or bowel* adenocarcinoma 
or bowel* carcinoma) ) OR AB ( (bowel* cancer* or bowel* neoplasm* or bowel* tumo*r* 
or bowel* adenocarcinoma or bowel* carcinoma) )  
S12  TI ( (il?eoc?ecum cancer* or il?eoc?ecum neoplasm* or il?eoc?ecum tumo*r* or il?eoc?ecum 
adenocarcinoma or il?eoc?ecum carcinoma) ) OR AB ( (il?eoc?ecum cancer* or il?eoc?ecum 
neoplasm* or il?eoc?ecum tumo*r* or il?eoc?ecum adenocarcinoma or il?eoc?ecum 
carcinoma) )  
S11  TI ( (il?eoc?ecal cancer* or il?eoc?ecal neoplasm* or il?eoc?ecal tumo*r* or il?eoc?ecal 
adenocarcinoma or il?eoc?ecal carcinoma) ) OR AB ( (il?eoc?ecal cancer* or il?eoc?ecal 
neoplasm* or il?eoc?ecal tumo*r* or il?eoc?ecal adenocarcinoma or il?eoc?ecal carcinoma) )  
S10  TI ( (caecum cancer* or caecum neoplasm* or caecum tumo*r* or caecum adenocarcinoma 
or caecum carcinoma) ) OR AB ( (caecum cancer* or caecum neoplasm* or caecum tumo*r* 
or caecum adenocarcinoma or caecum carcinoma) )  
S9  TI ( (c?ecal cancer* or c?ecal neoplasm* or c?ecal tumo*r* or c?ecal adenocarcinoma or 
c?ecal carcinoma) ) OR AB ( (c?ecal cancer* or c?ecal neoplasm* or c?ecal tumo*r* or c?ecal 
adenocarcinoma or c?ecal carcinoma) )  
S8  TI ( ( c?ecum cancer* or c?ecum neoplasm* or c?ecum tumo*r* or c?ecum adenocarcinoma 
or c?ecum carcinoma) ) OR AB ( ( c?ecum cancer* or c?ecum neoplasm* or c?ecum tumo*r* 
or c?ecum adenocarcinoma or c?ecum carcinoma) )  
S7  TI ( (rectosigmoi* cancer* or rectosigmoi* neoplasm* or rectosigmoi* tumo*r* or rectosigmoi* 
adenocarcinoma or rectosigmoi* carcinoma) ) OR AB ( (rectosigmoi* cancer* or rectosigmoi* 
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neoplasm* or rectosigmoi* tumo*r* or rectosigmoi* adenocarcinoma or rectosigmoi* 
carcinoma) )  
S6  TI ( (sigmoid cancer* or sigmoid neoplasm* or sigmoid tumo*r* or sigmoid adenocarcinoma or 
sigmoid carcinoma) ) OR AB ( (sigmoid cancer* or sigmoid neoplasm* or sigmoid tumo*r* or 
sigmoid adenocarcinoma or sigmoid carcinoma) )  
S5  TI ( (colon* cancer* or colon* neoplasm* or colon* tumo*r* or colon* adenocarcinoma or 
colon* carcinoma) ) OR AB ( (colon* cancer* or colon* neoplasm* or colon* tumo*r* or colon* 
adenocarcinoma or colon* carcinoma) )  
S4  TI ( (rectal cancer* or rectal neoplasm* or rectal tumo*r* or rectal adenocarcinoma or rectal 
carcinoma) ) OR AB ( (rectal cancer* or rectal neoplasm* or rectal tumo*r* or rectal 
adenocarcinoma or rectal carcinoma) )  
S3  TI ( colorectal cancer* or colorectal neoplasm* or colorectal tumo*r* or colorectal 
adenocarcinoma or colorectal carcinoma ) OR AB ( colorectal cancer* or colorectal 
neoplasm* or colorectal tumo*r* or colorectal adenocarcinoma or colorectal carcinoma )  
S2  (MH "Intestinal Neoplasms+")  
S1  (MH "Colorectal Neoplasms+")  
 
PsycINFO: Ovid. 1806 to November Week 4 2011 
1st December 2011 
 
1. ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
2. ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ 
or adenocarcinoma$)).ti,ab. 
3. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
4. ((sigmoid$ or rectosigmoi$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
5. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or 
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$)).ti,ab. 
6. (bowel$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
7. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
8. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
9. (hepatic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
10. (splenic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
11. or/1-10 
12. exp Health Promotion/ 
13. health promotion.tw. 
14. promot$ health.tw. 
15. Health Education/ 
16. health education.tw. 
17. Mass Media/ 
18. Social Marketing/ 
19. social marketing.tw. 
20. campaign$.tw. 
21. or/12-20 
22. Awareness/ 
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23. (aware$ or knowledge$ or attitude$ or recogni$).tw. 
24. 22 or 23 
25. (delay$ or late or later or early or earlier or postpone$ or wait$ or accept$ or deny or denial or 
promot$).tw. 
26. (helpseeking or diagnos$ or present$ or detect$ or attend$ or consult$ or seek or sought or refer 
or treatment or care).tw. 
27. 25 and 26 
28. (symptom$ and (detect$ or identif$)).tw. 
29. 27 or 28 
30. 11 and 21 and 24 
31. 11 and 21 and 29 
32. 30 or 31 
33. limit 32 to English language 
 
HMIC: Ovid. 1979 to September 2011 
1st December 2011 
 
1. exp Colorectal cancer/ 
2. ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
3. ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ 
or adenocarcinoma$)).ti,ab. 
4. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
5. ((sigmoid$ or rectosigmoi$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab. 
6. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or 
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$)).ti,ab. 
7. (bowel$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
8. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
9. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
10. (hepatic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
11. (splenic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
12. exp Health promotion/ 
13. health promotion.tw. 
14. promot$ health.tw. 
15. exp Health education/ 
16. health education.tw. 
17. patient education/ 
18. Mass media/ 
19. social marketing/ 
20. social marketing.tw. 
21. campaign$.tw. 
22. or/12-21 
23. or/1-11 
24. 22 and 23 
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Social Policy and Practice: Ovid.  
29th November 2011 
 
1     ((colorect$ or colo rect$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab.  
2     ((colon or colonic) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ 
or adenocarcinoma$)).ti,ab.  
3     ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab.  
4     ((sigmoid$ or rectosigmoi$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).ti,ab.  
5     ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ 
or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$)).ti,ab.  
6     (bowel$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab.  
7     (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab.  
8     (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab.  
9     (hepatic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab.  
10     (splenic flexur$ adj (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab.  
11     or/1-10  
12   (bowel$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or 
adenocarcinoma$)).ti,ab. 
13  12 not 11 
 
 
Dissertation and Theses A & I: ProQuest. 1861-present 
30th November 2011 
  
#3 #1 OR #2 
#2  all(“bowel cancer*” OR “bowel neoplasm*” OR “bowel tumo*r*” OR “bowel adenocarcinoma” 
OR “bowel carcinoma”) AND all(((health promotion) OR (promot* health) OR (health 
education) OR (patient education) OR media OR (social marketing) OR campaign*)) AND 
all((aware* OR knowledge* OR attitude* OR recogni* OR (((delay* OR late OR later OR early 
OR earlier OR postpone* OR wait* OR accept* OR deny OR denial OR promot*) NEAR/20 
(helpseeking OR diagnos* OR present* OR detect* OR attend* OR consult* OR seek OR 
sought OR refer OR treatment OR care))))) 
#1 all(“colorectal cancer*” OR “colorectal neoplasm*” OR “colorectal tumo*r*” OR “colorectal 
adenocarcinoma” OR “colorectal carcinoma” OR “colon* cancer*” OR “colon* neoplasm*” OR 
“colon* tumo*r*” OR “colon* adenocarcinoma” OR “colon* carcinoma” OR “rectal cancer*” OR 
“rectal neoplasm*” OR “rectal tumo*r*” OR “rectal adenocarcinoma” OR “rectal carcinoma”) 
AND all(((health promotion) OR (promot* health) OR (health education) OR (patient 
education) OR media OR (social marketing) OR campaign*)) AND all((aware* OR knowledge* 
OR attitude* OR recogni* OR (((delay* OR late OR later OR early OR earlier OR postpone* 
OR wait* OR accept* OR deny OR denial OR promot*) NEAR/20 (helpseeking OR diagnos* 
OR present* OR detect* OR attend* OR consult* OR seek OR sought OR refer OR treatment 
OR care))))) 
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TRIALS REGISTERS 
 
UK Clinical Research Network (UKCRN ): NIHR.   
http://public.ukcrn.org.uk/search/  
9th December 2011 
6 results 
 
Title / Acronym : awareness: 6 results 
 
1. Awareness AD / MIDAS - A comprehensive profile of awareness in early stage dementia 
2. Awareness of illness following brain damage - Emotional biases in anosognosia following brain 
damage - awareness of illness following brain damage  
3. RAW - Does Increasing Research Awareness Impact on Accrual? A Feasibility Study 
4. Risk factor awareness in patients with coronary heart disease. - Risk factor awareness in patients 
with coronary heart disease. 
5. Self awareness in autism - The psychological functioning of children and adolescents with autism 
6. Upper Limb position awareness in Complex Regional Pain Syndrome (CRPS) and other 
rheumatological - Upper Limb position awareness in Complex Regional Pain Syndrome (CRPS) 
and other rheumatological pain conditions 
 
 
Clinical Trials.gov: US NIH. 
http://clinicaltrials.gov/ct2/search  
9th December 2011 
 
Found 8 studies with search of: (bowel cancer OR colorectal cancer) AND awareness 
Found 8 studies with search of: (bowel or colorectal) AND (tumor OR tumour) AND awareness 
1 Recruiting  Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care 
Decision-Making  
Conditions:  Stage IV Colorectal Cancer;   Dignity Therapy 
Intervention:  Behavioral: Dignity Therapy 
 
2 Active, not 
recruiting  
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE 
Project)  
Condition:  Colorectal Cancer 
Interventions:  Behavioral: TELECARE;   
Behavioral: Pamphlet intervention 
 
3 Completed  Colorectal Cancer Screening Intervention Trial  
Conditions:  Colorectal Cancer;   Colorectal Cancer Screening 
Interventions:  Other: Control;   
Other: Reduced out of pocket expense;   
Behavioral: one on one education;   
Behavioral: Group education 
 
4 Recruiting  Screening for Familial Colorectal Cancer (CRC) Patients  
Condition:  Colorectal Cancer 
Intervention:  Behavioral: Questionnaire 
 
5 Recruiting  Using Effective Provider-Patient Communication to Improve Cancer Screening 
Among Low Literacy Patients  
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Conditions:  Cervical Cancer;   Breast Cancer;   
Colorectal Cancer 
Intervention:  Other: Cancer risk communication skills training 
 
6 Completed  
Has 
Results  
Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination  
Condition:  Anus Neoplasms 
Intervention:   
 
7 Active, not 
recruiting  
Study of Economic Circumstances, Service Utilization, and Service Needs Among 
Older Colon Cancer Patients  
Condition:  Colon Cancer 
Intervention:  Behavioral: Patient Interview 
 
8 Available  Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human 
Tumor Cells  
Conditions:  Endometrial Cancer;   Colon Cancer 
Intervention:  Other: Tissue sample from tumor 
 
 
 
metaRegister of Controlled Trials  
12th December 2011 
 
1 Results for “Colorectal cancer awareness” 
http://www.controlled-trials.com/mrct/search.html  
 
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project) Status: 
Active, not recruiting Source of record: NIH ClinicalTrials.gov Register (International) - subset of 
randomised trial records 
 
 
GREY LIT SEARCHING 
 
Searched Open Grey  
http://www.opengrey.eu/search/request?q=colon+cancer&b=20 
9th December 2011 
17 results 
 
Searched for “cancer promotion” to give 17 results 
 
Lifestyle and cancer A health promotion programme in the ...  
Hope, A. ; Kelleher, C. ;  
1995 ; I - Miscellaneous 
Early cancer detection Possibilities of the systematic early ...  
1983 ; I - Miscellaneous 
The myth-makers in health promotion Is the randomised control ...  
Weston, R. ;  
1997 ; U - Thesis 
Cancer control in practice A training and resource handbook for ...  
Ulster Cancer Foundation, Belfast ; Spiers, A. ;  
0000 ; I - Miscellaneous 
Cancer in the workplace Health promotion and care programmes - a ...  
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Ulster Cancer Foundation, Belfast ;  
0000 ; I - Miscellaneous 
Young people's attitudes to sunbathing  
Howard, W. ;  
1997 ; I - Miscellaneous 
Social representations of cancer and their role in health ...  
Tanner, S.J. ;  
1997 ; U - Thesis 
Adolescent smoking cessation in schools A teachers guide on how ...  
Ulster Cancer Foundation, Belfast ;  
0000 ; I - Miscellaneous 
Cancer research Interim statement of the research promotion  
1984 ; I - Miscellaneous 
Help your patient stop Smoking cessation in primary health care  
Murphy, B. ; Ulster Cancer Foundation, Belfast ;  
1990 ; I - Miscellaneous 
Preventing skin cancer Guidance for local authorities  
1998 ; I - Miscellaneous 
The Yorkshire TV skin cancer campaign, developmental research ...  
Tones, K. ;  
1996 ; I - Miscellaneous 
Raising Awareness of Grey Literature in an Academic Community ...  
Lin, Yongtao (University of Calgary) ; Vaska, Marcus (University of Calgary) ;  
2009 ; K - Conference [Text available online] 
Investigation on carcinogenic responses of polychlorinated ...  
Bock, K.W. ; Schwarz, M. ;  
1999 ; I - Miscellaneous 
Messages about breast screening Guidelines for health promotion ...  
Austoker, J ;  
1995 ; R - Report 
Health promotion Social cognitions and testicular self ...  
Pee, B.C.G. ;  
1997 ; U - Thesis 
Cancer mortality in Ireland 1976-1986  
Seymour, C. ; Herity, B. ; Moriarty, M.J ;  
1989 ; R - Report 
 
 
American Society of Clinical Oncology (ASCO): http://www.asco.org/ 
9th December 2011 
20 results 
 
Title: awareness  
Body Text: colorectal  
 
The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree 
relatives (FDR) for CRC screening.  
C. Arslan 
Abstract   2010 ASCO Annual Meeting - Category: Gastrointestinal (Colorectal) Cancer - 
Colorectal Cancer    
Background: We aimed to determine awareness and knowledge levels of CRC patients and FDR 
on CRC screening. Methods: Patients who were being treated or followed at our center and their 
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FDR were asked to complete a questionnaire on CRC screening with c... (More)  
Home > Meetings > Abstracts  
Awareness and penetration of KRAS mutation testing in the treatment of patients with metastatic 
colorectal cancer.  
F. Ciardiello 
Abstract   2010 ASCO Annual Meeting - Category: Gastrointestinal (Colorectal) Cancer - 
Colorectal Cancer    
Background: The tumor mutation status of codons 12 and 13 of the KRAS gene is a predictive 
biomarker in patients (pts) with metastatic colorectal cancer (mCRC). KRAS testing may be used 
to direct epidermal growth factor receptor (EGFR)-targeting mono... (More)  
Home > Meetings > Abstracts  
Community health attitude transformation through colon cancer prevention awareness campaign, 
Lubbock Colorectal Cancer Demonstration Project (LCCDP).  
D. Vugrin  
Abstract   2008 ASCO Annual Meeting - Category: Gastrointestinal (Colorectal) Cancer - 
Colorectal Cancer    
Background: Over 80% of colorectal cancer (CRC) can be prevented from occurring and most 
deaths could be avoided if the best currently available screening and treatment technology is 
applied to the entire population at risk according to the American ... (More)  
Home > Meetings > Abstracts  
The awareness and knowledge levels of colorectal cancer ...  
Virtual Presentation   2010   2010 ASCO Annual Meeting - Track: Gastrointestinal 
(Colorectal) Cancer - Session: Gastrointestinal (Colorectal) Cancer (General Poster 
Session)    
Presenter: Cagatay Arslan  
2010 ASCO Annual Meeting Presentation.    Session: Gastrointestinal (Colorectal) Cancer 
(General Poster Session).  
Home > MultiMedia > Virtual Meeting  
Cancer Awareness Dates | Cancer.Net  
Cancer Awareness Dates: March | Cancer.Net  
Leadership Perspectives: ASCO Sets Standards for Quality Care in Oncology, Raises 
Awareness about Barriers to Quality at the National and International Levels  
By Allen S. Lichter, MD ASCO Executive Vice President and Chief Executive Officer ASCO 
continues to be a leader in the national effort to encourage the development of guidelines and 
programs to safeguard patient access to high-quality...  
Home > Meetings > Annual Meeting > Past Annual Meetings > 2007 Annual Meeting > 2007 
ASCO Daily News > Monday, June 4, 2007 Section B  
Cancer Awareness Dates: September | Cancer.Net  
Cancer Awareness Dates: November | Cancer.Net  
Cancer Awareness Dates: April | Cancer.Net  
Cancer Awareness Dates: February | Cancer.Net  
Cancer Awareness Dates: May | Cancer.Net  
Cancer Awareness Dates: October | Cancer.Net  
Cancer Awareness Dates: July | Cancer.Net  
Cancer Awareness Dates: June | Cancer.Net  
Cancer Awareness Dates: January | Cancer.Net  
Cancer Awareness Dates: August | Cancer.Net  
Cancer clinical trials (CCT) awareness and attitudes in cancer survivors (Ca surv).  
R. L. Comis 
Abstract   2006 ASCO Annual Meeting - Category: Health Services Research - Health Services 
Research    
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Background: A web-based survey of attitudes and awareness of Ca surv towards CCT was performed 
from 3-4, 2005. The survey instrument was developed jointly by the Coalition of Cancer Cooperative 
Groups (CCCG) and Northwestern Univ (NU) and executed by... (More)  
Cancer Awareness Dates: December | Cancer.Net  
Cancer Awareness Dates: Introduction | Cancer.Net  
 
European Society for Medical Oncology (ESMO): http://www.esmo.org/  
12th December 2011 
25 results 
 
Results 1-3 of about 4 for bowel cancer awareness campaigns 
Other Organizations - European Society for Medical Oncology (ESMO)  
... of use; useful links: Anti-cancer campaigns; Associations of ... presenter Lynn Faulds 
Wood, who beat advanced bowel cancer. ... fourteen years to raise awareness of this ...  
www.esmo.org/footer-menu/useful-links/patients-support/other-organizations.html - 46k 
Research on cancer prevention, detection and management in low ...  
... cancer downstaging. Improved awareness among the public and health care providers, 
supported by ... of head and neck, breast, cervix and large-bowel cancers among ...  
annonc.oxfordjournals.org/content/21/10/1935.full 
[PDF] Global status report  
... approaches to cancer prevention and control: primary prevention, early detection, 
treatment and palliative care. Early diagnosis based on awareness of early ...  
www.esmo.org/fileadmin/media/pdf/2011/UN_summit/2010_WHO_Global_Status_Report_on_NCDs.pdf 
- 2011-07-27 
 
Results 1-10 of about 13 for colorectal cancer awareness campaigns 
[PDF] Microsoft PowerPoint - El Saghir ESMO Stockholm 2008 Epidemiol ...  
... Anti-Cancer programs Awareness Campaigns ... Rectal, Breast Cancer ... Bladder (11.7%) Lymphoma 
(15.6%) Colorectal (11.2%) Lung (16%) Stomach (9.8%) Leukemia (9.5%) ...  
www.esmo.org/.../977/19/El%20Saghir%20ESMO%20Stockholm%202008%20Epidemiol%20Prev%20Final-
2.ppt.pdf - 2008-10-07 
Scaling up cancer diagnosis and treatment in developing countries ...  
... States, multidrug therapy for colorectal cancer costs up ... as a result of community 
public awareness campaigns and the ... staff in clinical breast cancer examination ...  
annonc.oxfordjournals.org/content/21/4/680.full 
[PDF] Proposed Outcomes Document for the United Nations High-Level ...  
... and morbidity of gastric, colorectal, breast, cervical ... policies and public awarenes  
campaigns to reduce ... to: o Diagnostic technologies, radiotherapy and cancer .   
www.esmo.org/.../2010/un_summit/1_NCD_Alliance_Proposed_Outcomes_Document_for_UN_High_Level_Summit.pd  
- 2011-04-04 
[PDF] COUNTRY COMMITMENTS MADE AT THE UN HIGH LEVEL MEETING ON THE ...  
... most common cancers in Serbia: cervical, breast, colorectal ... early screening and raising 
public awareness Target to establish 54 cancer treatment centres ...  
www.esmo.org/.../pdf/2011/UN_summit/Final_Country_Commitments_at_HLM_plenaries_and_round_tables.pdf 
- 2011-11-03 
[More results fromwww.esmo.org/fileadmin/media/pdf]  
International Organizations - European Society for Medical ...  
... support the development of new colorectal cancer groups ... early detection of lung cancer; 
provides practical ... to increase research funding, awareness and resources ...  
www.esmo.org/footer-menu/useful-links/patients-support/international-organizations.html - 44k 
European Organizations - European Society for Medical Oncology ...  
... first European organisation dedicated to colorectal cancer (CRC) and ... ED), the European 
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Breast Cancer Coalition, is ... Coalition works to raise awareness of breast ...  
www.esmo.org/footer-menu/useful-links/patients-support/european-organizations.html - 46k 
Research on cancer prevention, detection and management in low ...  
... misuse of very limited resources, eg in ineffective public education campaigns. ... cancer 
downstaging. Improved awareness among the public and health care providers ...  
annonc.oxfordjournals.org/content/21/10/1935.full 
Cancer initiatives in Sudan  
... treatments are available; breast, cervical and oral cancer. This article describes 
some preventive approaches through public awareness campaigns and education ...  
annonc.oxfordjournals.org/content/17/suppl_8/viii32.abstract 
The perspective and role of the medical oncologist in cancer ...  
... in, awareness campaigns to inform the population about the importance of screening 
programs and disseminate information about how to prevent cancer. ...  
annonc.oxfordjournals.org/content/19/6/1033.full 
[PDF] INESME MARZO 09-ING.indd, page 104 @ Preflight  
... All of this would have repercussions on the awareness of politicians and policy ... better 
health policies which improve all aspects of care for cancer patients in ...  
www.esmo.org/fileadmin/media/image/2010/news/INESME_report.pdf - 2010-01-21 
Epidemiology of invasive cutaneous melanoma  
... that, in contrast to squamous cell cancer of the ... adjuvant therapy and 
greater public 
awareness leading to ... that extensive public education campaigns have been 
...  
annonc.oxfordjournals.org/content/20/suppl_6/vi1.full 
 
Results 1-7 of about 8 for colon cancer awareness campaigns 
International Organizations - European Society for Medical ...  
... creating such a platform Global Colon Cancer aims to ... early detection of lung cancer; 
provides practical ... to increase research funding, awareness and resources ...  
www.esmo.org/footer-menu/useful-links/patients-support/international-organizations.html - 44k 
[PDF] mdn366 1033..1035  
... the lungs, cervix, breast, prostate and colon. ... to, and participate in, awareness 
campaigns to inform ... and disseminate information about how to prevent cancer. ...  
www.esmo.org/fileadmin/media/pdf/policies/esmo_policy_aao.pdf - 2008-12-22 
[PDF] Global status report  
... breast and colon cancer, and depression ... across the four broad approaches to cancer 
prevention and ... Early diagnosis based on awareness of early signs and symptoms ...  
www.esmo.org/fileadmin/media/pdf/2011/UN_summit/2010_WHO_Global_Status_Report_on_NCDs.pdf 
- 2011-07-27 
[More results fromwww.esmo.org/fileadmin/media/pdf]  
[PDF] Microsoft PowerPoint - El Saghir ESMO Stockholm 2008 Epidemiol ...  
... Page 11. Colo-Rectal Cancer in Arab Countries ... Surgery colon and liver; Radiation, 
Expensive ... Awareness campaigns towards private physicians is recommended ...  
www.esmo.org/.../977/19/El%20Saghir%20ESMO%20Stockholm%202008%20Epidemiol%20Prev%20Final-
2.ppt.pdf - 2008-10-07 
[MS POWERPOINT] ESMO CANCER PATIENT ADVOCACY FORUM  
... recommendation on screening for colon, cervical and ... promote relevant information 
campaigns for the ... Vigorously promote cancer awareness in the general public ...  
www.esmo.org/fileadmin/media/presentations/824/LCT10001657.ppt - 2007-12-12 
The perspective and role of the medical oncologist in cancer ...  
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... the lungs, cervix, breast, prostate and colon. ... to, and participate in, awareness 
campaigns to inform ... and disseminate information about how to prevent cancer. ...  
annonc.oxfordjournals.org/content/19/6/1033.full 
[PDF] INESME MARZO 09-ING.indd, page 104 @ Preflight  
... All of this would have repercussions on the awareness of politicians and policy ... better 
health policies which improve all aspects of care for cancer patients in ...  
www.esmo.org/fileadmin/media/image/2010/news/INESME_report.pdf - 2010-01-21 
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 8.2. Appendix: Inclusion and exclusion criteria 
 
Inclusion and exclusion criteria 
The titles and abstracts of records identified by the search strategy will be examined for relevance by 
one reviewer. Full papers of any potentially relevant records will be obtained where possible and 
screened by one reviewer. The relevance of each study to the review and the decision to 
include/exclude studies will be made according to the inclusion criteria detailed below. Any studies 
which give rise to uncertainty will be reviewed by a second reviewer with involvement of a third 
reviewer when necessary. 
• Population 
o Include: 
 General public  
o Exclude: 
 Populations at increased risk (family members, genetic predisposition) or 
previously treated patients. 
 
• Intervention 
o Include: 
 Awareness campaigns or interventions aiming to increase early detection of 
CRC and intended for delivery to whole communities where the recipients 
are not selected according to risk (familial risk, CRC history or 
screening status). 
• This may include media campaigns, leaflets distributed in community 
settings, on-line websites, in-pharmacy or in-surgery interactive 
screens, interventions delivered by healthcare staff to patients and so 
on.   
• Campaigns may target a particular community, such as non-English 
language speakers or socioeconomically disadvantaged communities 
• Campaigns may aim to promote early presentation through 
o Awareness of symptoms 
o Increased up-take of existing screening programmes 
• Campaigns may be about “any cancer” but must include outcomes 
about colorectal cancer 
 
o Exclude: 
 Awareness campaigns or interventions intended for delivery to selected 
individuals (e.g. those who are not compliant with screening guidelines, 
those at increased risk) 
 Interventions which were delivered in full or in part through one-to-one 
contact with a professional or lay health worker 
 Studies which investigate the effects of new screening programmes with or 
without awareness campaigns  
 Prevention awareness campaigns (e.g. healthy eating) 
 Awareness campaigns targeting healthcare staff and which only report 
outcomes relating to them.  
 
 
• Comparator 
o Include 
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 Any  
 No intervention 
 No comparator (single arm before-after studies are to be included) 
 
• Outcomes 
o Include if reports one or more of: 
 Additional GP visits 
 Additional referrals 
 Numbers entering screening programmes 
 Time from symptom discovery to diagnosis 
 Proportion at each stage at presentation 
 Survival/mortality 
 Data on patients hearing or seeing campaign material 
 Change in knowledge relating to colorectal cancer 
 Change in beliefs  
 
o Exclude: 
 Post-intervention measure taken on same day as intervention. 
 Where only outcomes relate to change in health behaviours (i.e. increased 
healthy eating, cessation of smoking...etc.) 
 Where only outcomes are qualitative 
 
• Study design 
o Include: 
 Any. It is not always possible or appropriate to run RCTs, and alternative 
designs are not always robust.   
 Only include studies which  
• collected data on outcomes before and after the intervention (include 
sampling of populations before and after general population 
intervention, or same participants before and after tested 
intervention) 
• or where data is available before and after (i.e. numbers entering 
screening  in X year, compared to after the campaign/programme) 
• or randomised trials with a comparison group (i.e. before and after 
data not reported, but where data after the intervention - which allow 
a comparison between the intervention group and the 
control/comparator group - are available) 
o Exclude: 
 Before and after studies for which post-intervention is measured on the same 
day as the intervention. 
Also exclude abstracts, editorials, commentaries, reviews of primary papers (other than for reference 
to primary papers) and theses. 
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 8.3. Appendix: Quality assessment scoring guidelines. 
 
Score: 
Y = bias/error avoided 
N = bias/error not avoided 
U = unclear 
 
RCT studies 
 
Bias Item Notes 
Selection bias Random sequence 
generation 
Consider whether the method used to generate the allocation 
sequence should produce comparable groups. 
 Allocation 
concealment 
Consider whether the method used to conceal the allocation 
sequence meant intervention allocations could have been 
foreseen in advance of, or during, enrolment. 
Performance 
bias 
Blinding of 
participants and 
personnel 
Consider whether measures were used to blind study 
participants and personnel from knowledge of which 
intervention a participant received.  
 
Note whether blinding was  
a) effective (score No if blinding broken) 
b) possible (score No if not possible) 
 
In cases where blinding not performed, consider whether this 
is likely to have introduced performance bias (e.g. were 
outcomes subjective?) 
Detection bais Blinding of outcome 
assessment 
Consider whether measures were used to blind outcome 
assessors from knowledge of which intervention a participant 
received.  
 
Note whether blinding was  
a) effective 
b) possible 
 
In cases where blinding not performed, consider whether this 
is likely to have introduced detection bias (e.g. were 
outcomes subjective?) 
Attrition bias Incomplete outcome 
data 
Attrition bias due to amount, nature or handling of incomplete 
outcome data. 
 
Yes: 
- no attrition, or small enough not to affect results 
- ITT with imputation 
 
No:  
- large losses with no imputation 
Reporting 
bias 
Selective reporting 
or outcomes 
Bias due to selective reporting of outcomes 
 
Check if all outcomes listed in methods section are reported. 
 
69 
 
This review will not go back to look at protocols. 
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Non-randomised controlled trials, before-after studies and interrupted time series. 
Bias Item Notes 
Selection 
bias 
Representativeness of 
cohort/group to whole 
population of interest 
 
Consider how the cohorts/study arm participants 
were recruited and  whether exposed and non-
exposed/before-after cohort/groups are likely to be:  
 
- representative of whole community targeted (as 
defined by the study authors, not in relation to this 
review) 
 
E.g. self-selection to participate? Where recruited 
from? Drawn from different cultural/ethnic groups? 
Different GP practices? Consecutive unselected 
sample of patients? Random sample? 
 
 Comparativeness of 
cohort/groups to each other 
 
Consider whether the groups are similar to each 
other in all but exposure to the intervention  
 
Consider whether the analysis has taken into account 
all baseline distributions of potential/known 
confounders through adjustment in analysis 
Performance 
bias 
Blinding of participants and 
personnel 
Note whether blinding was  
a) effective (score No if blinding broken) 
b) possible (score No if not possible) 
 
Score Yes for participants if geographical blinding 
occurred (i.e. areas far enough apart to reasonably 
expect participants to be unlikely to have interaction 
with the other cohort/group) 
 
BA, IS: score Yes if participants unaware that 
questionnaire relates to evaluation of recent 
campaign and unaware whether they are pre or post 
intervention 
Detection 
bais 
Blinding of outcome 
assessment 
Blinding of outcome assessors should be possible in 
most cases, though is rarely done!  
 
Where self-report and participants are aware of 
intervention, score No. 
Attrition bias Incomplete outcome data If none or small number, score Yes 
 
BA, IS studies: if response rate poor or different 
between before and after surveys, score N. If missing 
responses not corrected for, and are large, score N 
Reporting 
bias 
Selective reporting or 
outcomes 
Check if all outcomes listed in methods section are 
reported. 
 
Reviewer did not consult protocols. 
Other bias Temporal/other confounders BA/ITS studies - were potential temporal 
trends/confounders identified and accounted for in 
the analysis? 
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8.4.  Appendix : Prisma flow chart of study selection process 
 
 
 
 
 
72 
 
 8.5.   Appendix: Excluded studies 
 
Studies excluded at full text, with reasons for exclusion.     
                               
Author and year Study design Primary reason for 
exclusion 
Comments  
Anonymous[48] NR Abstract only  
Anonymous[49] NR Untraceable reference 
 
 
Adams 1996[50] Before-after Publication type  
 
 
Aragones 2010[51] RCT Selected participants Selected unscreened 
participants, involved 
appointment with GP 
Bagai et al 2007[52] Cross-sectional Study design  
Bassett & Goulston 
1978[53] 
NR Publication type   
Bayer 2008[54] Before-after Publication type  
Berkley 1992[55] NA Publication type  
Blumenthal et al 
2010[56] 
RCT Selected participants  Selected unscreened 
participants 
Brasca et al 1986[57] NR Abstract only  
Braun et al 2005[58] RCT One-to-one attention  
Brown & Potosky 
1990[59] 
NA No intervention  
Causey & Greenwald 
2011[60] 
Before -after Outcome recorded on the 
same day 
 
Centers for Disease 
Control and 
Prevention 2003[61] 
NA Study design  
Chan & Vernon 
2008[62] 
RCT Selected participants  e-mail letters to unscreened 
patients 
Connelly 2007[63] NR Untraceable reference  
Costanza et al 
2007[64] 
RCT One-to-one attention Mailed booklet and telephone 
counselling 
Dietrich et al 
2007[65] 
RCT One-to-one attention Included telephone 
conversation 
Eisinger et al 
2011[66] 
Cross-sectional No intervention  
Emmons et al 
2004[67] 
RCT Outcome recorded on 
same day 
 
Everett 1999[68] RCT Publication type  
Fenton 2011[69] NA Publication type Comment 
Fitzgibbon et al 
2007[70] 
Wolf et al 2005[71] 
RCT Selected participants  Patients selected on basis of 
CRC status; one-on-one 
attention provided 
Frazier et al 1987[72] NR Outcome recorded on 
same day 
 
Gimeno-Garcia et al RCT Outcome recorded on  
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Author and year Study design Primary reason for 
exclusion 
Comments  
2009[73] same day 
Gossey 2011[74] RCT Publication type Thesis 
Greenwald 2006[75] Before-after Outcome recorded on 
same day 
 
Greenwald & 
Edwards 2010[76] 
Cross-sectional Study design  
Hart et al 1997[77] Before-after Outcome recorded on 
same day 
 
Hoffman et al 
1983[78] 
NA No intervention  
Holt et al 2011[79] Before-after One-to-one attention  
Jerant et al 2007[80] RCT Outcome recorded on 
same day 
 
Katz et al 2004[81] Cross-sectional No intervention  
Keighley 2004[82] NR Publication type  
Lasser et al 2011[83] RCT One-to-one attention Involves patient navigator 
Lawsin et al 2007[84] Cross-sectional No intervention  
Lee et al 2009[85] Before-after New programme  
Lopez et al 2010[86] Case study New programme  
Loss et al 2006[87] Case study Non-English language  
Ma et al 2009[88] Quasi-
experimental 
One-to-one attention Involves patient counsellor 
Mahon 1995[89] Case study No outcomes of interest  
Makoul et al 2009[90] Before-after Outcome recorded on 
same day 
 
Marcus et al 2005[91] RCT One-to-one attention Materials tailored to patient 
characteristics 
Maxwell et al 
2011[92] 
RCT Selected participants  Selected unscreened 
participants, small group 
sessions with a follow-up 
letter 
Maxwell et al 
2010[93] 
 Selected participants  Selected unscreened 
participants, small group 
sessions with a personalised 
follow-up letter 
Mayer et al 2004[94] NR Untraceable reference  
Mazor et al 2010[95] Qualitative Qualitative study  
Meade et al 1994[96] RCT Outcome recorded on 
same day 
 
Menon et al 2008[97] RCT and 
qualitative 
Outcome recorded on 
same day 
 
Miesfeldt et al 
2010[98] 
Case study Study design  
Morgan et al 
2010[99] 
RCT Outcome recorded on 
same day 
 
Murff 2005[100] NR Publication type  
Myers et al 2007[101] RCT Selected participants  Selected unscreened 
participants, collected survey 
data, tailored print materials 
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Author and year Study design Primary reason for 
exclusion 
Comments  
to characteristics 
Myers et al 2008[102] Prospective 
cohort study 
Study design  
Nguyen et al 
2010[103] 
Before-after Selected participants  Selected never screened 
participants, included one to 
one telephone back-up 
O’Riordain & Gorey 
1996[104] 
NR Publication type  
Pahil et al 2010[105] RCT Abstract only  
Parente et al 
2011[106] 
Before-after Abstract only  
Paul et al 2003[107] Before-after No information on 
intervention 
 
Percac et al 
2009[108] 
RCT One-to-one attention Involved patient navigator 
Philip et al 2010[109] Before-after Selected participants  Selected never screened 
participants, involved one to 
one attention from Doctor 
Potter et al 2010[110] RCT Selected participants  Selected unscreened 
participants, involved one to 
one attention from patient 
educator 
Powe & Weinrich 
1999[111] 
Before-after Selected participants  Selected unscreened 
participants. Viewed video on 
colorectal screening depicting 
peers. 
Power et al 
2011[112] 
NR No intervention  
Provenzano 
2007[113] 
NR Publication type  
Pullyblank et al 
2002[114] 
Cross-sectional No intervention  
Reubsaet et al 
2009[115] 
Before-after No data relating to 
colorectal cancer 
 
Robb et al 2006[116] RCT Outcome recorded on 
same day 
 
Royse & Dignan 
2009[117] 
Before-after One-to-one attention One-to-one telephone 
conversation 
Ruffin et al 2007[118] RCT Selected participants  Selected participants who had 
never been screened to view 
website. 
Rutledge et al 
2006[119] 
Quasi-
experimental 
Lifestyle prevention 
intervention 
 
Schroy et al 
2008[120] 
Cross-sectional Study design  
Sequist et al 
2009[121] 
RCT Selected participants Selected unscreened 
participants.  
Seeff et al 2008[122] NR Study design  
Shankaran et al RCT Staff intervention with no  
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Author and year Study design Primary reason for 
exclusion 
Comments  
2009[123] data on patient outcomes 
Smith et al 2010[124] RCT Selected participants  Selected unscreened 
participants. Viewed material 
designed for people with low 
literacy. 
Strock et al 
2008[125] 
NR Untraceable reference  
Subrahmanian et al 
2011[126] 
Before-after Outcome recorded on 
same day 
 
Trevana et al 
2008[127] 
RCT Selected participants Selected unscreened 
participants 
Tu et al 2006[128] RCT Selected participants  Selected unscreened 
participants, unclear whether 
patient educator delivered 
one-on-one sessions. 
Ueland et al 
2006[129] 
Quasi 
experimental 
Outcome recorded on 
same day 
 
Vernon et al 
2011[130] 
Misra et al 2011[131] 
RCT Selected participants  Selected unscreened 
participants, involved printed 
letter for discussion with 
physician 
Ward et al 2006[132] Non-
randomised 
Controlled trial 
No outcome of interest  
Wardle et al 
1999[133] 
RCT Outcome recorded on 
same day 
 
Wardle et al 
2003[134] 
RCT Selected participants  Selected unscreened and 
“probably only get screened” 
participants, included posting 
psycho-educational material 2 
weeks prior to screening 
invitation. 
White et al 2006[135] Case study One-to-one attention Involved one-to-one 
telephone conversations.  
Williamson &Wardle 
2002[136] 
Case study Publication type  
Wu et al 2010[137] Before-after Selected participants  Selected patients at high risk, 
involved patient navigators 
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 8.6.  Appendix: CRC survival data 
 
The CRC survival data within the model was updated. Data giving ‘net survival’ at 1 and 3 years by 
both age and stage at diagnosis from the International Cancer Benchmarking Partnership (ICBP) was 
used.[34] Net survival is the hypothetical survival you would expect to see assuming no other cause 
deaths occurred i.e. net survival is higher than overall survival. For long-term survival estimates (e.g. 
5/10 year survival) a multivariable excess hazard model was used to obtain an unbiased estimation of 
‘net survival‘, by contrast to the conventional relative survival approaches.[138,139]  
 
Estimates of cancer survival for colon (C18) and rectum (C19-C20,C218) were combined to provide 
an estimate of CRC survival. Data by 5-year age bands was converted to data by age using linear 
interpolation.  
 
For each age and stage of diagnosis a different model of survival was applied. The models fitted were 
mixture models which assume that a fixed proportion of persons survive; this is a similar approach to 
the ‘cure fraction model’.[140] The mortality of the non-surviving component was assumed to be 
exponential to allow for easy implementation within the markov model structure. The survival 
proportion was estimated using estimates of 5-year survival from England cancer registry data of 
diagnoses between 1997 and 2001.[33] This means we assume that the cohort of patients alive after 
5 years do not experience higher mortality than the reference population. Further data on long-term 
survival by age and stage could improve the accuracy of these estimates in the future. The data used 
did not incorporate a survival projection to capture improvements in survival over time.  
 
Generally the data shows lower net survival for CRC diagnosed in later stages and for older persons; 
the net survival for ages 50, 60, 70 and 80 is illustrated in Figure 12.  
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The cost-effectiveness model incorporates both deaths due to CRC and deaths due to other causes. 
Data on other cause mortality were taken from Interim Life Tables, United Kingdom, Office for 
National Statistics and adjusted to remove mortality from CRC.[141,142] The two mortality rates were 
applied within the model in the following way: 
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• Mortality from CRC = 1-Net survival 
• Mortality from other causes = (1-Netsurvival)*(1-Other cause survival) 
• Overall survival = Net survival - (1-Netsurvival)*(1-Other cause survival) 
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8.7.   Appendix: Model parameter values 
 
Awareness campaign parameters  mean source
Increased presentation rates stage A 10% Pilot campaign data
Increased presentation rates stage B 10% Pilot campaign data
Increased presentation rates stage C 10% Pilot campaign data
Increased presentation rates stage D 10% Pilot campaign data
Duration of increase in presentation rates (months) 1 Pilot campaign data
Increased screening uptake rate 0 Personal communication, NHS cancer screening, 2012
Cost of campaign per person  £        0.14 Personal communication, DoH, 2011
Cost of GP visit  £           36 Curtis 2010
Cost of secondary care attendance for suspected low er GI cancer  £         200 Tappenden et al 2011
Number of additional GP addendances pp 0.0014 Pilot campaign data
Number of additional sec. care appointments pp 1.526E-05 Pilot campaign data
Proportion of additional visits w hich are extra 0.5 Assumption
Cost of addition GP and sec. care attendances  £      0.026 Calculated from other parameters  
 
Natural history parameters  mean source
Normal epithelium to LR adenomas - age 30            0.02 Model calibration
Normal epithelium to LR adenomas - age 50            0.02 Model calibration
Normal epithelium to LR adenomas - age 70            0.05 Model calibration
Normal epithelium to LR adenomas - age 100            0.01 Model calibration
LR adenomas to high risk adenomas - age 30            0.01 Model calibration
LR adenomas to high risk adenomas - age 50            0.01 Model calibration
LR adenomas to high risk adenomas - age 70            0.01 Model calibration
LR adenomas to HR adenomas - age 100            0.00 Model calibration
HR adenomas to Dukes A CRC - age 30            0.03 Model calibration
HR adenomas to Dukes A CRC - age 50            0.02 Model calibration
HR adenomas to Dukes A CRC - age 70            0.05 Model calibration
HR adenomas to Dukes A CRC - age 100            0.12 Model calibration
Normal epithelium to CRC Dukes A            0.00 Model calibration
Preclinical CRC: Dukes A to Dukes B            0.51 Model calibration
Preclinical CRC: Dukes B to Dukes' C            0.69 Model calibration
Preclinical CRC: Dukes C to Stage D            0.71 Model calibration
Symptomatic presentation w ith CRC Dukes A            0.04 Model calibration
Symptomatic presentation w ith CRC Dukes B            0.18 Model calibration
Symptomatic presentation w ith CRC Dukes C            0.37 Model calibration
Symptomatic presentation w ith CRC Dukes D            0.74 Model calibration
Proportion of cancer incidence classif ied as proximal            0.38 Cancer Registrations 2007, England
Average number of adenomas present in patient w ith at least one adenoma            1.90 Winaw er et al 1993
Proportion of advanced adenomas classif ied as HR adenomas            0.75 FS trial data
Proportion of HR pp requiring annual surveillance            0.29 NHS BCSP data
LR polypectomy, transition probability LR            0.10 England BCSP data, Martinez et al 2009
LR polypectomy, transition probability HR            0.04 England BCSP data, Martinez et al 2009
LR polypectomy, transition probability CRC            0.00 England BCSP data, Martinez et al 2009
IR polypectomy, transition probability LR            0.16 England BCSP data, Martinez et al 2009
IR polypectomy, transition probability HR            0.09 England BCSP data, Martinez et al 2009
IR polypectomy, transition probability CRC            0.00 England BCSP data, Martinez et al 2009   
Harm/complications parameters  mean source
COL (w ithout polypectomy) perforation rate 0.0% FS UK screening trial data, Atkin et al 2002
COL (w ith polypectomy) perforation rate 0.3% Bow el cancer screening pilot 2nd round evaluation, Table 5.2
COL Probability of death follow ing perforation 5.2% Gatto et al 2003
FS (w ithout polypectomy) perforation rate 0.0% FS UK screening trial data, Atkin et al 2002
FS (w ith polypectomy) perforation rate 0.01% FS UK screening trial data, Atkin et al 2002
FS Probability of death follow ing perforation 6.5% Gatto et al 2003
FS probability of hospitalisation for bleeding 0.03% FS UK screening trial data, Atkin et al 2002
COL probability of hospitalisation for bleeding 0.3% FS UK screening trial data, Atkin et al 2002
Repeat rates  mean source
gFOBT mean number of tests completed            1.08 Assumption based on number of gFOBTs returned w ithin 7 days
iFOBT mean number of tests completed            1.01 NHS BCSP data, Italian iFOBT screening programme Zorzi et al 2009
FS Probability test repeated on a later day            0.02 FS UK screening trial data, Atkin et al 2002
COL repeat test rate            0.07 NHS BCSP data
Screening participation parameters  mean source
FOBT participation for each screening round            0.54 NHS BCSP data
Proportion completing at least one FOBT screening round            0.63 NHS BCSP data
FOBT participation for a round for those w ho comply w ith at least one FOBT 
test            0.85 NHS BCSP data
COL follow -up compliance FOBT screening            0.79 NHS BCSP data
COL follow -up compliance FS screening            0.96 FS UK screening trial data, Atkin et al 2002
COL surveillance compliance            0.83 NHS BCSP data
FS screening compliance            0.85 Assumed same as for FOBT, Atkin et al 2010  
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Health-related quality of life parameters  mean source
Utility value cancer free            0.80 Ara et al 2010
Utility value CRC            0.70 Ara et al 2010
Resource Use parameters  mean source
Cost of gFOBT screen (non-compliers)  £        2.03 Southern Hub screening costings model
Cost of gFOBT screen (normal result)  £        3.36 Southern Hub screening costings model
Cost of gFOBT screen (positive result)  £      11.94 Southern Hub screening costings model
Cost of iFOBT screen (non-compliers)  £        6.43 Southern Hub screening costings model
Cost of iFOBT screen (normal result)  £        7.37 Southern Hub screening costings model
Cost of iFOBT screen (positive result)  £      16.20 Southern Hub screening costings model
Cost of FS screen excl. FS exam (non-compliers)  £        5.02 Southern Hub screening costings model
Cost of FS screen excl. FS exam (not referred to COL)  £        6.01 Southern Hub screening costings model
Cost of FS screen excl. FS exam (referred to COL)  £      14.84 Southern Hub screening costings model
Cost of FS (w ithout polypectomy)  £         453 NHS reference costs, screening centre estimates
Cost of FS (w ith polypectomy)  £         453 NHS reference costs, screening centre estimates
Proportion of LR adenomas being referred for COL follow ing FS 3% FS trial data
Cost of COL (w ithout polypectomy)  £         563 NHS reference costs and screening centre estimates
Cost of COL (w ith polypectomy)  £         563 NHS reference costs and screening centre estimates
Cost of treating bow el perforation (major surgery)  £      5,089 NHS reference costs
Cost of admittance for bleeding (overnight stay on medical w ard)  £         278 NHS reference costs
Pathology cost for adenoma  £           26 NHS reference costs 08/09, histopathology
Pathology cost for cancer  £           26 NHS reference costs 08/09, histopathology
Discount rate for costs 3.5% NICE methods of techonology appraisal 2008
Discount rate for health outcomes 3.5% NICE methods of techonology appraisal 2008
Willingness to pay threshold  £    20,000 NICE methods of techonology appraisal 2008  
 
Test Characteristics  mean source
gFOBT Sensitivity for LR adenomas            0.01 Model calibration
gFOBT Sensitivity for HR adenomas            0.12 Model calibration
gFOBT Sensitivity for CRC            0.24 Model calibration
gFOBT Specif icity age 50            0.99 Model calibration
gFOBT Specif icity age 70            0.97 Model calibration
FS Sensitivity for LR adenomas            0.22 Model calibration
FS Sensitivity for HR adenomas            0.71 Model calibration
FS Sensitivity for CRC            0.62 Model calibration
FS Specif icity            1.00 Assumption due to nature of the test
iFOBT Sensitivity for LR adenomas            0.05 Model calibration
iFOBT Sensitivity for HR adenomas            0.32 Model calibration
iFOBT Sensitivity for CRC            0.63 Model calibration
iFOBT Specif icity age 50            0.98 Model calibration
iFOBT Specif icity age 70            0.93 Model calibration
COL Sensitivity for LR adenomas            0.77 Van Rijn et al 2006
COL Sensitivity for HR adenomas            0.98 Van Rijn et al 2006
COL Sensitivity for CRC            0.98 Bressler et al 2007
COL Specif icity            1.00 Assumption due to nature of the test  
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 8.8. Appendix: Modelling technicalities 
 
 
The awareness campaign resulted in an increase in the number of cases of CRC diagnosed during 
March 2011. Although data is currently somewhat incomplete due to reporting bias it looks like this is 
a short-term increase. 
 
 
Adjusting annual transition probabilities for a short term increase in the transition rate 
Consider a transition with a normal annual transition probability of p. 
Consider an increased incidence, i (i=1.1 for a 10% increase) for x months of a 12-month period. 
 
The normal x-months transition probability is 1-(1-p)^(x/12). 
 
The annual transition probability associated with an increase i for x months then the previous rate for 
the remaining 12-x months is: 
 
p’ =i*[1-(1-p)^(x/12)]+{1-(1-p)^((12-x)/12)} *{1-i*[1-(1-p)^(x/12)]} 
=1-i+ip+(i-1)*(1-p)^((12-x)/12) 
 
Example: 
  Normal annual transition probability p 0.5 
Increased incidence observed i 1.2 
Duration of increase (months) x 6 
New annual transition probability p' 0.54 
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 8.9. Appendix: Interventions included in the review 
 
Study Intervention Local 
healthcare 
staff 
involvement 
Method of 
design 
Control Topics covered (NB: 
not always well 
reported) 
Aim to increase self-presentation 
De Nooijer 
2004[11] 
Targeted several common 
cancers. 
  
Int 1: Tailored letter* 
Int 2:  Dutch Cancer Society 
leaflet  
 
No Theory-based UC Both covered “similar” 
topics: 
early detection, risk 
perception, symptoms, 
passive detection, 
seeking medical help, 
attitudes, social 
influences, self 
efficacy, information 
relating to self 
examination  
WoSCAP[12] Targeted CRC 
Focus on early detection due 
to signs and symptoms. High 
profile media campaign on 
television, ministerial launch, 
direct mailshot of leaflet, 
competition, work place 
initiatives, photographic 
exhibition, proactive stories in 
media, local events and 
initiatives with charities and 
voluntary organisations. 
Materials developed in 
response to research with 
members of the public.  
Yes – Included 
accredited 
training 
programme for 
professionals, 
symposia, 
newsletters and 
blogs. 
Concepts 
trialled with 
focus groups 
UC Signs and symptoms: 
recent change in 
bowel habit or going 
more often than 
normal, looser 
motions, or alternating 
with constipation, 
bleeding from your 
bottom, feeling bowel 
is not empty after “a 
number two”. Who is 
most at risk (age, 
gender, family history, 
polyps, IBD, high fat 
diet with low intake of 
vegetables/fibre) 
Lyon 2009[13] Targeted breast, bowel and 
lung cancer. Highly varied 
intervention. Local teams made 
up of professionals and 
volunteer community members 
all involved in design. 
Awareness-raising measures 
aimed to be culturally 
appropriate and delivered in 
accessible and engaging way. 
Included plays, poems, bingo, 
games, songs, beer mats and 
media coverage of such 
activities. Multiple venues 
including doctors waiting 
rooms, out-patient 
departments, health clinics, 
pubs, bingo halls, community 
halls, mosques, faith groups 
etc. 
No Community 
involved in 
design and 
delivery 
NA Raise awareness of 
symptoms. Early 
presentation means 
better chance of cure. 
Reduce fear. 
Ramsay 
YearNR[14] 
Targeted CRC 
Ran for one month.  
Case study in local press, radio 
interviews with doctors, 
billboard, hit squads (face to 
face campaigning) and ad-
vans on match day with press 
coverage. Targeted bookies, 
Yes – Practice 
managers to 
brief GPs, to 
support 
campaign in 
surgery and 
provide data 
Focus groups 
to identify 
needs and 
trial materials 
NA Signs and symptoms: 
“If you notice bleeding 
from the bottom or a 
lasting change in 
bowel habits, Play it 
safe - go to your 
doctor.” “Most cases 
of bowel cancer occur 
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pubs, DIY stores, barbers, 
local shops, social clubs. Beer 
mats, posters. Z-cards for use 
in shops. Stand-up 
performances at comedy 
events. 
Materials developed in 
response to research with 
members of the public. 
in men over 50” 
Aim to increase screening rates 
Blumenthal 
2005[16] 
Targeted several common 
cancers. Culturally sensitive. 
Community led. Attractive and 
colourful materials with 
representations of African- 
Americans. Brochure, a flyer, 
two posters and yard signs, 
bus adverts, newspapers, 
mass media.  Activities (health 
fairs and educational 
programs, community 
presentations etc). 
Combination of delivery 
mechanisms via “gatekeeper” 
members of the community, 
including non-traditional 
channels such as hair styling 
establishments.  
Yes – 
healthcare 
staff 
encouraged to 
disseminate, 
encourage 
lifestyle change 
and to follow-
up referrals.   
Community 
involved in 
design and 
delivery 
UC Lifestyle change, 
encourage screening, 
increase self efficacy, 
knowledge of risk and 
survivability,  
Nguyen 2010[15] CRC campaign.  
Vietnamese-language CRC 
screening media campaign 
(through Vietnamese-language 
media outlets including 
newspapers, radio, TV), 
distribution of health 
educational material (bilingual 
booklet, penlight. Distributed 
through businesses, health 
agencies, events, and 
organizations in the 
Vietnamese community), 
hotline.  
Yes - medical 
education 
seminars, 
distribution of 
patient 
counselling 
materials, 
reminder items, 
training 
newsletter, 
DVDs. 
Focus groups 
to identify 
needs, 23 
individuals 
trialled 
materials 
NR, 
assume 
UC 
CRC screening 
knowledge, attitudes, 
beliefs. 
Powe 2004[17] CRC campaign. 
Int 1: Cultural and Self- 
empowerment Group. Centres 
received a video "Telling the 
story... To live is God's will" 
(culturally relevant  with well-
known community members 
and leaders), calendar, poster, 
brochure and flier  
Int 2: Modified cultural group. 
Centres received the video 
only 
No Unclear ACS 
video  
Knowledge, incidence, 
screening guidelines 
even in absence of 
symptoms, importance 
of early detection, risk 
factors, nutrition, 
attitudes, beliefs, 
preventive health care 
from spiritual 
perspective, Faecal 
occult blood test 
(FOBT) 
demonstration.  
Katz 2007[18] CRC campaign. Educational 
intervention to address 
barriers, culturally acceptable 
to all racial groups.  Based on 
ACS screening guidelines. 
ACS coordinator trained ACS 
area coordinators who in turn 
trained the local ACS project 
volunteers (n =179) who 
delivered intervention. 
No Focus groups 
to identify 
needs and 
trial materials 
NA Knowledge, statistics, 
risk factors, diagnosis, 
treatment, self- 
efficacy, addresses 
barriers, readiness for 
change, and increase 
awareness of benefits 
of early detection.  
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Messages to the public via 
educational classes, direct 
mailings, brochures, media 
campaigns by community 
newspapers and local radio 
stations. Messages to 
healthcare providers via 
waiting-room posters, monthly 
examination-room materials 
and chart reminders. 
Broadwater 
2004[22] 
Targeted CRC and skin 
cancer. Advertising/awareness 
campaign: television, radio, 
print, public relations, local 
media talent recruited as 
spokespeople, and physicians 
made public appearances. 
Local television broadcast a 
live colonoscopy.   
Yes – 
physicians 
involved in 
delivery 
Telephone 
survey to 
gauge current 
knowledge, 
attitudes and 
behaviours. 
Focus group 
trailed 
materials. 
NA Key messages “The 
fact is, there are no 
early warning signs of 
colon cancer.”  “If 
you’re 50 or older, call 
your doctor to find out 
which colon cancer 
screening option is 
right for you.”  “A 
simple test saves 
lives.” 
Katz 2011[20] CRC campaign. Culturally 
sensitive media campaign, 
based on social cognitive 
theory.  Local cancer Initiative 
in partnership with academic 
researchers developed a 
media campaign. Campaign 
image and message was used 
in all campaign materials, 
including the billboard, posters, 
brochures, and newspaper 
ads.  
Yes – Local 
agency 
included some 
local 
healthcare 
staff. 
Community 
needs 
assessment 
used to gauge 
knowledge 
and 
behaviours. 
Local agency 
involved in 
design. Survey 
to use to get 
feedback on 
materials.  
NA “Get Behind Your 
Health! Talk to Your 
Doctor About Colon 
Cancer Screening.” 
Information about 
CRC, CRC risk factors 
and symptoms, CRC 
screening, and the 
message that CRC 
screening saves lives. 
Zhou 2011[21] CRC, prostate and skin 
campaign. National multimedia 
"Screen for Life" campaign, 
regional and state campaigns. 
Included bilingual element to 
reach Hispanic Americans. 
Campaign materials, TV and 
radio announcements, 
newspaper articles, regional 
educational programmes.  
No Unclear  NA NR 
*This intervention is not within the inclusion criteria for this review 
Int, intervention; UC, usual care; sig, statistically significant; non-sig, not statistically significant; ACS, American Cancer Society, 
NR, not reported; NA, not applicable; CRC, colorectal cancer; FOBT, Faecal occult blood test; IBD, Inflammatory Bowel 
Disease 
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8.9  Appendix: Summary of outcomes 
 
Study Time line Campaign 
awareness 
Knowledge Attitudes GP visits, GP referrals, 
Screening uptake, 
Diagnoses 
Aim to increase self-presentation 
de Nooijer 
2004[11] 
T0 = baseline  
Int at 3 
weeks 
T1 = 6 weeks  
T2 = 6 
months 
NR T1 
Pairwise 
comparison: SIG 
difference 
Int1:Int2:UC  
T1 & T2 
Passive detection  and 
help seeking intention, 
Int 2 SIG at T1 only  
NR 
WoSCAP[12] Delivered 
over several 
months 
T = NR 
NRCT data 
Sig NR,  ↑  in 
TV, radio, 
posters and 
leaflets 
BA, IS data 
Sig NR, ↑ in 
knowledge of 
bleeding, ↓ or ↔ 
in change 6 other 
symptoms not 
covered by TV 
advert 
Comparative data NR GP referrals ↑, sig NR, FV NR 
Lyon 
2009[13]* 
Baseline = 
12 month 
retrospective 
chart review 
T0 = 
intervention 
commences 
T1 = 2 weeks 
T2 = 12 
months 
NR NR NR T2 
Referrals: SIG ↑in urgent 
referrals  
 
Diagnoses: SIG ↑ in 
diagnoses via urgent referral; 
NON-SIG ↑ in diagnoses with 
no spread** 
Ramsay 
Date NR 
Delivery 
length 
unclear 
Baseline = 
prior 3 
months   
T0 = 1 month 
int starts 
T1 = 3 
months post 
Int 
Sig NR, ↑ in 
recall of a 
campaign 
Sig NR, ↑ in 
awareness of  all 
symptoms, 
bleeding most 
recognised, ↑ 
awareness of age 
risk and 
importance of 
early diagnosis 
Sig NR, ↓ in personal 
concern, ↑in 
confidence in noticing 
symptoms 
Sig NR, ↓ in GP 
consultations. FV NR 
Aim to increase screening 
Blumenthal 
2005[16] 
T0 = 2 year 
int starts  
T1 = NR 
Some SIG 
and some 
NON-SIG 
results 
across both 
Atlanta sites 
and Nashville 
sites 
NR NR Screening (FOBT): Altanta 
sites: Int SIG ↑ than UC.  
FV: 56.6% screened 
Nashville sites: Non- sig ↓.  
FV: 51.9% screened 
Nguyen 
2010[15] 
T0 = 3 year 
int starts 
T1 = approx. 
2 years from 
T0 
 
 
SIG ↑ in 
awareness of 
booklet, 
newspaper, 
radio and TV 
ads.  
NON-SIG ↑ 
for reading 
newspaper 
article  
 
SIG ↑ in 
knowledge of 
FOBT and colon 
polyps.  
NON-SIG ↑ for 
sigmoidoscopy.  
SIG ↑ belief that need 
screening s/c; ↓s/c is 
painful; ↑might get 
colon cancer; ↑need 
FOBT even if healthy; 
↓ fear s/c will find 
cancer  
NON-SIG ↓ worry; fear 
FOBT will find cancer;  
↔ expected 
troublesomeness of s/c  
Screening:  SIG ↑ ever had 
screening s/c, FV: 65%;  
Had screening s/c in last 5 
years, FV:44% 
NON-SIG ↑ in ever had 
FOBT, FV: 71%;  
had FOBT in past year 
FV:36% 
Powe 
2004[17] 
T0 = 12 
month int 
start 
NR Repeated 
measures 
ANOVA to T2: Int 
NR Screening at T2: 
Sig NR, but Int1>Int2>UC  
FV:61%, 46%, 15% 
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T1 = 1 week,  
T2 = 6 
months 
T3 = 12 
months 
1 SIG greater ↑ 
(Int 2 & UC NR) 
respectively 
Katz 
2007[18] 
T0 =  6 to 8 
month int 
starts 
T1 = 0 to 2 
months 
 
NR Non-sig  SIG ↑ in positive beliefs 
about screening  
NON-SIG for perceived 
barriers to screening. 
 
 
Screening: NON-SIG ↑.  
FV: 55.6% screened 
Broadwater 
2004[22] 
T0 = 1 month 
int starts 
T1 = one 
month 
↑ in number 
who saw, 
read or 
heard; sig 
NR 
NR ↑ in number who 
reported changing 
behaviour; sig NR 
Data unclear. 
Katz 
2011[20] 
T0 = 3 
months int 
starts 
T1 = 1 month 
69% (42/61) 
reporting 
seeing a 
message. No 
comparator. 
NR NR NR 
Zhou 
2011[21] 
Baseline = 1 
year after 
intervention 
started 
T1 = 6 years 
after 
intervention 
started 
NR NR NR Endoscopy or home FOBT  
SIG ↑ both groups 
FV Hispanics: 26.6% 
FV white non-Hispanics: 
44.2% 
*interim results – year one of two-year project.  Project dissolved when Improvement Foundation ceased trading. 
**No spread defined as Dukes’ A or Dukes’ B 
GP, General practitioner/primary care physician; SIG or sig, statistically significant; NON-SIG, not statistically significant; Int, 
intervention; T0, baseline; T1, first follow-up; T2, second follow-up; T3, third follow-up; UC, usual care;  NR, not reported; ↓, 
decreased; ↑, increased; ↔, no change; s/c, colonoscopy or sigmoidoscopy; FOBT, faecal occult blood test; FV, final value 
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